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Introduction.
The antipyretic-analgesic action of 
salicylate and the well-known stimulation of respiration 
resulting from large doses of the drug have generally 
been attributed to a central action on the nervous 
system. Doubts about the validity of this view were 
first aroused when it was found that the analgesic 
action of salicylate in the acute arthritis of rheumatic 
fever was invariably accompanied by diminution in 
joint swelling (Reid, Watson & Sproull, 1950). This 
observation was supported by the fact that no 
precise site of action in the brain is known where a 
drug may relieve pain without affecting consciousness. 
Furthermore, doubts about a central action were 
strengthened by the establishment of salicylate as a 
metabolic stimulant in man (Cochran 1952) and by 
appreciation of the specificity of salicylate in 
relieving rheumatic fever (Gaddum 1955)• Finally the 
possibility of a central action was rejected by the 
discovery that the metabolic action was peripheral and 
could be demonstrated with tissue slices (Sproull 1954), 
which had no connections with the nervous system.
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This metabolic stimulant effect of salicylate 
has been clearly demonstrated in plants, in animal 
tissues and in whole animals including man. In 1957 
Reid showed that the oxygen consumption of wheat 
coleoptile segments was increased when grown in 
salicylate solution. Reports of animal tissue response 
were confused, including a negligible effect as well 
as ones of stimulation and depression according to the 
drug concentration used (Alwall 1959, Lutwak-Mann 
1942 and Fishgold et al 1951). The matter was resolved 
however in 1954 when Sproull showed the true pattern 
of salicylate stimulation in mouse liver slices over 
the complete dose range. In rabbits (Reid 1952), 
dogs (Dodd et al 1957, Tenney & Miller 1955) and rats 
(Meade 1954), parenterally administered salicylate was 
shown to increase oxygen consumption. More recently, 
oral administration of the drug to man both in health 
(Cochran 1952) and in disease (Cochran 1952, Alexander 
& Johnson 1956) has proved that the metabolic 
stimulating effect could also be demonstrated in the 
human. The precise dose-response relations however 
have still to be determined.
The main purpose of this work was to determine
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the dose- or coneentrâtion-response relations between 
oxygen consumption and serum salicylate level in man.
The obvious difficulty of obtaining normal subjects 
for long-term salicylate administration in order, to . 
establish a control series had to be overcome by 
referring to a group of convalescent rheumatic 
patients who were being maintained on aspirin and were 
clinically and biochemically normal at the time of 
the investigations. When the concentrâtion-response 
relation was established in these patients, observations 
were extended to a miscellaneous group of patients and 
the results compared. This group included an obese 
woman, a diabetic receiving aspirin in a trial of its 
hypoglycaemic activity, and several myxoedematous 
patients whose resting metabolic rates were character­
istically subnormal and who were being treated with 
aspirin to study the effect on the metabolic rate and 
on the manifestations of myxoedema.
In addition to defining the coneentrâtion- 
response relationship in these patients, measurement 
of carbon dioxide production as well as oxygen 
consumption was made in a selected group of convalescent 
controls over a similar period of aspirin therapy
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and the pattern of change in respiratory quotient 
was determined.
A quantitative investigation of the 
respiratory response to salicylate was. also undertaken 
in convalescent and myxoedematous patients to clarify 
the relationship between metabolic stimulation and 
respiratory stimulation after salicylate. When this 
was completed a comparison between salicylate and 
2:4-dinitrophenol was made to find out whether or not 
these two stimulants had a similar action regarding 
oxygen consumption and respiration, and the comparison 
was extended to observations of the glycogenolytic 
action of both salicylate and dinitrophenol in the 
rat.
—4 —
Chapter 1.
The Metabolic Response to Salicylate-.
The quantitative aspects of the 
relationship between salicylate administration and 
metabolic stimulation in man have been examined. 
Difficulty in obtaining normal individuals to take 
salicylate for prolonged periods has already been 
mentioned and made it necessary to confine the 
investigation to patients convalescent from rheumatic 
fever. Clinical signs of active rheumatic disease were 
absent, the erythrocyte sedimentation rate and plasma 
fibrinogen were normal and there was no evidence of 
metabolic or biochemical abnormality when the 
investigation was carried out. Thus, while the 
metabolism of these patients did not differ in any 
known respect from that of normal individuals it is 
emphasised that they were employed as controls or, 
rather, reference standards for the purposes of this 
investigation only.
The patients received 3 to 10 g. aspirin 
daily in divided doses. By adjusting the doses, a wide
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scatter’over the therapeutic dose-range was obtained 
in each case. Estimations of oxygen consumption were 
made with a Benedict-Roth apparatus three to four times 
each week oyer a period.of two to. four weeks at about 
9 a.m. Patients were either fasting or were given 
one cup of tea and half a slice of buttered toast at 
least two hours previously. Duplicate tracings of 
oxygen consumption were obtained and the results were 
accepted only if they were within 10 ml. oxygen/min. 
of each other at standard temperature and pressure 
(s.t.p.). This is equivalent to a variation of +3?^  
oxygen consumption of a man's average rate, taken as 
300 ml./min. at s.t.p. The untreated control oxygen 
consumption of each subject obtained after salicylate 
therapy had been discontinued was either the lowest 
of three or more consecutive daily runs, or was the 
same on two consecutive daily runs. This value 
provided the base-line from which the effect of 
salicylate administration on oxygen consumption was 
judged. Results have been expressed as a percentage 
of the normal basal metabolic rate (B.M.R.), determined 
by the standards of Robertson & Reid (1952) and 
adjusted for the surface area of the individual.
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Venepunctures were carried out immediately after the 
B.M.R. for the estimation of the serum drug level 
by the Trinder (1954) method.
Before detailed investigation of the 
convalescent patients was carried out, it was necessary 
to decide by preliminary experiment whether oral 
dose or serum concentration of the drug would be the 
more practical and accurate index of reference for the 
metabolic response. Guidance on this point was 
obtained by determining dose-response and concentrâtion- 
response curves in one patient. The results are shown 
in Table 1 (Appendix), where it will be observed that 
over a period of 15 days the dose was progressively 
increased every 2 days from 50 gr. to 82.5 gr.
(3.2 to 5.3 g.)/day, the serum salicylate steadily 
rising from 18 to 44 mg./ICO ml. and the oxygen 
consumption from 155 to 218 ml./min. at s.t.p.
This represented an overall increase in B.M.R. of 
about 40^.
The relation between dose of aspirin and 
B.M.R., and serum concentration and B.M.R. were 
examined separately and details of the results are 
shown in Fig. 1. From inspection of the two scatter
— 7—
Fig.l.
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As will be seen from the numbering of the observations 
in the coneentrâtion-response diagram in chronological 
order, no evidence of tolerance to the drug occurred 
during the period of investigation*
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diagrams, it was noted that although each set of points 
approximated to a straight line, the scatter was greater 
in the case of the dose-response diagram. ?rom the 
data shown, regression lines were drawn. The dose- 
response curve gave a correlation coefficient, r =
0.79 (P < 0.01) and the standard deviation of the 
scatter <r = The equation of the regression was
y = 0*68x + 55.25. The concentrâtion-response curve 
gave a correlation coefficient, r = 0.88 (P<0.001) 
and the standard deviation of the scatter cr = 4*64•
The equation of the regression was y = 0.98x + 69.5.
95^ confidence limits of the lines were drawn
(+15.27 for dose-response and +10.49 for concentrâtion-
response, Pig. 1).
The significance of the dose-response and 
concentration-response regression lines were each 
estimated by comparing the mean square and the 
residual mean square (Table 2). P ratio for dose- 
response = 15.1 (0.1 >P <1.0) and for concentration- 
response = 28.2 (P <0.1).
Thus preliminary investigation indicates 
that drug concentration is a suitable dose metameter. 
Neither is the choice of concentration rather than 
dose unexpected from pharmacological considerations
Table 2.
(a) Dose-response regression equation: 
y = G.60X+ 55.25. n =11#
Source of Sum of Degrees of Mean
variation squares Freedom squares
Due to regression 528.1 1 528.1
Residual 321.0 6 40.1
Total 849 9
Variance Ratio = 13.1 
Therefore 0.01 P C 0.001.
(b) Concentration-response regression equation: 
y = 0.98x + 69.5. n = 11.
Source of Sum of Degrees of Mean
variation squares Freedom squares
Due to regression 669.4 1 669.4
Residual 189.6 8 23.7
Total 859.0 9
Variance Ratio = 28.2 
Therefore P ^0.001.
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connected with oral therapy, such as variation in 
absorption and the comparatively long time required to 
attain a stable response for each particular dose.
Serum, concentration, on the other handj Is more closely 
related to its pharmacological site of action and it 
also furnishes an immediate measure of the drug 
circulating at the time of estimation of oxygen 
consumption.
For these reasons the serum concentration 
of salicylate was chosen as the reference index.for 
all the investigations which follow.
Serum Salicylate Concentration and Metabolic Rate in
Convalescents.
Concentration-response curves of seven 
convalescent patients, three males and four females, 
were determined. The ages of the patients ranged 
from 14 to 37 years. Particulars of the metabolic 
response of each patient to aspirin are given below, 
and a summary of the clinical data is given in Table 3 
(Appendix).
Patient C.W. (Case 1) a young man 25 years
- 11-
old, was studied for 20 days. During this time the 
serum salicylate ranged from 15 to 50 mg./lOO ml.
After aspirin administration was discontinued and no 
salicylate was detected in the blood, the normal 
resting B.M.R. was determined. The control B.M.R. 
after stopping aspirin was lOlÿ^ : the maximum
metabolic rate reached during treatment was 152^, 
and this coincided with the highest serum concentration 
of the drug. Eighteen observations were made and a 
closely correlated linear regression was derived: 
r = 0.91, (P <0.001) and the 95?^  confidence limits of 
the line only +4.79. The equation of the regression 
was y = 0.59x + 102.5 (Pig. 2 Table 4 (Appendix).
Patient S.H.(Case 2), a young woman of 
24 years was investigated over 18 days. Serum 
salicylate concentrations varied from 13 to 
51 mg./lOO ml. and the B.M.R. rose from 83^ to 122^# 
Because of this unusually low post-treatment value, 
this patient was readmitted to hospital at a later
1*51
date for investigation of thyroid function. I
uptakes of her thyroid gland, showed no abnormality 
and this, together with the complete absence of any 
clinical signs of myxoedema, ruled out the possibility
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of hypothyroidism. It was concluded that she had a 
low but normal resting metabolic rate which was within 
the limits quoted for normal British men and women in 
a recent report (Booyens & MeCanoe 1957).
Grood linear correlation was again shown 
between serum salicylate and B.M.R.% r = 0.92,
(P<*0*001) and the 95^ confidence limits of the 
regression line were +12.24. The equation of the 
regression was y = 0.94x + 71.8, (Pig. 3 Table 5).
Patient R.C. (Case 3) was a young man of 
23 years. Normal convalescence continued throughout 
the period of investigation. Eighteen observations were 
made during 28 days. Serum salicylate concentrations 
ranged from 6 to 49 mg./ICO ml. and the B.M.R. rose 
from a post-treatment value of 117^ to a maximum of 
149^ normal. The regression line drawn from these 
observations showed linearity, with a coefficient of 
correlation, r = 0.76 (P <0.001) and the 95?^  
confidence limits of the line +17.87. The equation 
of the regression was y = l.llx + 93.7 (Pig. 4 
Table 6).
Patient A.W. (Case 4) was a young man of
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18 years who was studied during convalescence during 
a period of 32 days. Pifteen observations were made. 
The range ir^serum salicylate concentration was 8 to 
52 mg./lOO ml. ; the B.M.R. rose to à maximum of 133?^ 
of normal from a non-treatment control value of 103?^ *
A close linear correlation was established, r = 0.93,
(P <0.001), and the 95?^  confidence limits of the line 
were +10.07. The equation of the regression was 
y = 0.85% + 86.2 (Pig. 5 Table 7).
Patient C. McC. (Case 5), a young woman 
aged 37 years, was studied during a convalescent 
period of 27 days. Fifteen observations were made 
while receiving treatment with aspirin, after which the 
customary establishment of the untreated control 
B.M.R. was determined after discontinuing aspirin.
The serum salicylate concentration varied from 10 to 
49 mg./lOO ml. This patient’s post-treatment B.M.R. 
was 102^ normal and the maximum achieved during therapy 
was 1665^ . Linear correlation between serum salicylate 
concentration and response was again shown,r = 0.91 
(P< 0.001). The 95^ confidence limits of the line 
were +15.94 and the equation of the regression was 
y = 1.20x + 105.1 (Pig. 6 Table 8).
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Patient J.McW» (Case 6), was a girl of 
16 years. Over a period of 32 days the serum 
salicylate concentration varied from 17 to 
74 mg./lOO ml., and her B.M.R*. rose, to a maximum of 
168^. The control post-treatment value was 95?^  
normal. The regression line constructed from 12 
observations showed linearity, the correlation 
coefficient, r = 0.88, (P <0.001). The scatter of . 
points in this individual was fairly extensive, the 
95^ confidence limits of the line being +30.1. The 
equation of the regression was y = 1.48x + 65.5 
(Pig. 7 Table 9).
Patient M.Cr. (Case 7), aged 14, was the 
last of the convalescent control patients to be 
studied over a period of 29 days. Fourteen 
observations were made while she was receiving salicylate 
therapy and her untreated control B.M.R. was then 
determined. Salicylate concentrations ranged from 
10 to 50 mg./lOO ml., and the B.M.R. rose from a 
control value of 96^ normal to a maximum of 151^.
The correlation coefficient of the linear regression 
so formed was r = 0.95, (P <0.001). 95% confidence
limits of the line were +15.2. The equation of the
- 15-
regression was j = 1.37x + 73.1 (Pig. 8 Table 10).
In each of the seven convalescent patients 
a linear correlation was established between the serum 
salicylate, concentration, eDepressed as mg./l00 ml., 
and metabolic stimulation. In every case the 
significance of the probability of linearity was 
<0.001/». (Table 11).
Before examining the results of the 
individual patients to find out whether a composite 
regression line could be established for the group as 
a whole, the relation of the individual lines to the 
patients’ ages was examined. Their ages and the 
slopes of the regression lines were as follows
Age in Regression Patient’s 
yrs. coefficient No.
b
14 1.37 7
16 1.48 6
18 0.85 4
23 1.11 3
24 0.94 2
25 0.59 1
37 1.20 5
Between the ages of 14 and 37 years no obvious trend
in the values of the regression coefficients was
noted when taken in ascending order of age of the
patients.
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The next step was to examine the seven 
regression lines on the same graph (Pig. 9) and it 
was observed that the difference of slopes and 
intercepts between the.convalescents was not great 
and the obvious question that arose was whether these 
seven convalescents could be regarded as one, as far 
as their metabolic stimulation from aspirin was 
concerned. This led to the construction of a composite 
concentration-response curve using the 104 pairs of 
observations in the seven cases. The initial non­
treatment values of the B.M.R. varied from patient to 
patient, so that a more accurate assessment of the 
degree of stimulation was obtained by expressing 
each observation as the increment of oxygen consumption
p
(AOg) in cals./m /hr. above the individual’s untreated 
control value.
The composite regression curve so fomed had 
a coefficient of correlation r = 0.896, (P <0.001).
The equation of the regression was y = 0.46x - 7.6, and 
the 95% confidence limits of the line were +5.94, which 
was a measure of the difference in response due to 
individual variation in this control group (Pig. 10, 
Table 12).
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Pig. 9.
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The main purpose in establishing this . 
concentration-response relationship in the convalescent 
rheumatic patients was to compare the metabolic 
response t o .aspirin in other, diseases,, particularly 
in myxoedema where the metabolic rate at the outset 
was below normal. Six patients with primary myxoedema 
were given a course of aspirin and observations of their 
oxygen consumption in relation to the serum concentration 
of salicylate were made.
Serum Salicylate Concentration and Metabolic Rate in
Myxoedema.
Concentration-response curves of six 
myxoedematous patients were constructed in exactly 
the same manner as that of the convalescent rheumatics 
except that the untreated control value of the B.M.R. 
was determined before starting salicylate administration. 
Particulars of each patient and the metabolic responses 
to salicylate will be presented before proceeding to 
examination of the group concentration-response curve.
Patient M.McM. (Case 8), a man of 52 years 
was thought to have had myxoedema for three to four
— 20—
years* He presented the classical stolid facies with
scaly appearance of the skin, and had recently
complained of incapacitating attacks of angina* He
was well built but was not overweight.. Radio-iodine ■
studies confirmed the diagnosis of myxoedema (4-hourly 
131uptake of I by the thyroid gland was 7*4^ of the 
dose administered, which was barely half of the minimal 
value accepted in cases of normal thyroid function). 
Oxygen consumption and serum salicylate were estimated 
on nine occasions over a period of 25 days including 
the basal control period for establishing a pre-treatment 
B.M.R.. The serum salicylate concentration varied from 
16 to 46 mg./ICO ml. and the B.M.R. rose from 76^ to 
108^ normal. No deleterious effects were noted at any 
point during the trial and no increase in anginal 
symptoms was noted even at the height of metabolic 
stimulation. A very close linear correlation was 
established between drug concentration and response, 
the correlation coefficient, r = 0*97, (P 40.001).
95^ confidence limits of the line were +6.8 and the 
equation of the regression was y = 1.08x + 59.1 
(Pig. 11, Table 15 (appendix).
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Patient A.Mel* (Case 9), a woman of 65 years 
had myzoedema which had been diagnosed some 10 years 
previously* For some time prior to this trial with 
salicylate she had been without adequate therapy and 
on admission complained of lethargy and angina of 
effort* Routine radio-iodine tests confirmed the 
diagnosis (uptake of by the thyroid four hours
after administration of the dose was 8*1^). Fifteen 
observations during a period of 25 days were made while 
she was receiving aspirin* Variation in salicylate 
concentration from 9 to 49 mg*/lOO ml* was accompanied 
by an increase in metabolic stimulation of up to 
117^ normal * The pre-treatment B.M.R. was A
linear regression was formed with a correlation 
coefficient, r = 0*93> (P CO.001) and 93^ confidence 
limits of the line +10.3* The equation of the 
regression was y = 0.99% + 69*2 (Fig. 12, Table 14).
Patient I.McGr. (Case 10) was an obese woman
of 72 years who presented as a case of long-established
myzoedema with retarded mental processes, deafness,
slurring of speech as well as the typical facies.
151I tests confirmed the diagnosis of hypothyroidism by 
a 4-hour uptake of the thyroid gland of 7.1?& of the
- 22-
dose. Additional injection of TSH established the 
myxoedema as primary* Tests of metabolic stimulation 
were carried out during 25 days* Seventeen 
observations were made, while the salicylate 
concentrations varied from 20 to 56 mg*/lOO ml. The 
pre-treatment B.M.R. was as low as 61^ and rose with 
treatment to 97/^  normal* Analysis showed a highly 
significant linear correlation, the coefficient 
r = 0.96, (p C 0.001). Small variation due to the 
individual’s response to a given dose was noted and the 
955^  confidence limits of the line were +6*4. The 
equation of the regression was y = 0.88x + 50.6 
(Pig. 13, Table 15).
Patient P.P. (Case 11) was a 72 year old 
woman, overweight and anaemic, with dry opalescent 
skin and typical appearance of hypothyroidism. 
Radio-iodine studies again confirmed the diagnosis.
She was investigated oveij|k period of 29 days. The 
serum salicylate level varied from 14 to 52 mg./lOO ml. 
during which 15 observations were made. Her pre­
treatment B.M.R. was 80^ and with aspirin a maximum 
of 114^ was reached* Analysis of the points showed 
a linear regression with a coefficient of correlation,
- 25-
r = 0.94, (P Co.001) and 95?^  confidence limits of the 
line +7.7. The equation of the regression was 
y = 0.85% + 69.4 (Pig. 14, Table 16).
Patient M.E. (Casé 12) was a woman of 45 
years who was thought to have had myxoedema for about 
a year. She was not obese but had been aware of a change 
of countenance and unusual lassitude. Radio-iodine 
studies confiimed myxoedema (^^^I uptake by the thyroid 
gland after 4 hours was 10.6^ of the dose given) and 
injection of TSH showed that it was a primary type.
B.M.R. *s v/ere carried out over a period of 28 days. 
Thirteen observations were made during which the 
salicylate concentration ranged from 16 to 
59 mg./lOO ml. This patient’s pre-treatment B.M.R. 
was 78?^  and the maximum reached during aspirin therapy 
was 115^ normal. The linear regression fomed by the 
points gave a correlation coefficient, r = 0.95 
(PCo.001). The 95^ confidence limits of the line 
were +9.8 and the equation of the regression was 
y = 0.95% + 62.5 (Pig. 15, Table 17).
Patient P.A. (Case 15), aged 52, was a tall 
well-built woman with myxoedematous appearance and
- 24-
complaining of anginal pain. Her B.M.R. was 80^
normal and the diagnosis was confirmed as before by
151estimation of I uptake of the thyroid (at 4 hours, 
11.1^). She was investigated oyer 20 days,.during, - 
which the serum salicylate concentration ranged from 
9 to 50 mg./lOO ml. and the B.M.R. rose as high as 
106?^ normal. Thirteen observations were made and a 
linear regression was again established. The 
correlation coefficient, r = 0.92 ( P C 0.001) and 
the 95?5 confidence limits of the line were +10.3.
The equation of the regression was y = 0.75% + 68.5 
(Pig. 16, Table 18).
These results indicate that the metabolic 
stimulating effect of salicylate in patients with 
myxoedema is also closely correlated with the serum 
salicylate concentration. A graphical summary of 
the data from all the myxoedematous patients is 
presented in Pig. 17 and details of their clinical 
particulars are summarised in Table 5.
The regression data are summarised in Table 11. A 
composite regression line was constructed from the 
82 points derived from all the observations on the 
myxoedemas, each one expressed as an increment of
- 25-
Pik. 17.
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the individual's value before treatment• The 
coefficient of correlation for the group as a whole
was r = 0.94 (P^O.OOl) and the 95^ confidence limits of
the. line were. +2.54. . The equation, of the. regression . .
was y = 0.29x - 4.26 (Pig. 18, Table 19).
Comparison of the Myxoedematous and the Convalescent
Rheumatic Croup.
Prom inspection of the composite lines 
of the convalescent rheumatics and the patients with 
myxoedema (Pigs. 10, 18), it was noted that the 
myxoedematous group approximated more closely to a 
linear function than did the convalescent group. This 
may be due to the nature of the disease process in 
myxoedema. The mental state is one of lethargy, 
although the patients are usually eager to cooperate. 
Slow deliberation is characteristic of any physical 
movement. It is therefore understandable that 
determination of a response like B.M.R. which is, to 
a large extent, dependent on the patient's ability 
and willingness to achieve a basal unemotional 
condition should be technically superior in those 
people whose existence tends toward the vegetative.
-27-
Fig. 18,
Composite regression line : myxoedematons 
patients, cases 8 to 13.
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This difference in individual variation in response 
was substantiated by the confidence limits of the two 
composite lines viz. +2.54 for the myxoedematous 
group and +5.94 for the reference group of convalescents 
(Tables 12 and 19).
It was also observed (Fig. 18) that the 
gradient of the myxoedematous group was considerably 
less steep than that of the convalescent rheumatic 
group (Fig. 10). The two lines were therefore 
examined for difference in slope and intercept:
Equation of regression line of myxoedematous group 
y^ = 0.29x^ - 4.26 
Equation of regression line of convalescent group
y2 = 0.46x2 - 7.6.
Analysis of variance of th^egression coefficients 
b^ = 0.29 (myxoedema) and b2 = O.46 (convalescent), 
gave
V/eighted average residual variance = 2.18.
2
Variance of their difference = 0.00031 = 0^2 
calculated t = (b^ “ ^ 2)^12 ^ 9.4.
For (n^ + n2) = 186 degrees of freedom, t^ = 1.96. 
Therefore calculated T >t^
It was therefore concluded that the slopes of the two 
groups were significantly different from one another.
-2 9-
The intercepts of the two lines were compared 
by using the formula:-
O' I — Oz
j  - L + - L  + To.;n, hi 2:
Expression (a) = 1.32, and is distributed as t.
For (n - 3) degrees of freedom i.e. 183, this 
distribution of t gave a less than IQfo degree of 
significance of difference.
It was concluded the lines showed no difference in 
intercept.
Summary of the Concentrâtion-Response Data.
A series of seven clinically normal 
convalescent rheumatics receiving oral aspirin was 
chosen as a standard reference group and measurement of 
change in oxygen consumption v/as made with different 
amounts of the drug in order to assay quantitatively 
the metabolic response. Using serum salicylate 
concentration as the abscissa and basal metabolic 
rate as the ordinate, linear correlation was derived 
in each case over the therapeutic dose range. A
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composite regression line was constructed and the 
responses of other individuals were compared with 
the response of the convalescents. A composite 
regression line foimed from data of myxoedematous 
patients showed a difference in gradient, though not 
in intercept. It was noted too that one other 
patient (Case 14, Fig. 19, Table 20), with simple 
obesity, showed a response to salicylate which 
approximated more closely to the response of the 
myxoedematous group, while the metabolic response of 
one diabetic patient (Case 15, Fig. 20, Table 21), 
treated with salicylate was indistinguishable from 
that of the convalescent group. No conclusion is drawn 
from these isolated cases.
It was concluded that over a period of 
2-4 weeks, the action of salicylate on the oxygen 
consumption may differ in different individuals, in 
particular where thyroid function is absent. In order 
to clarify the nature of this dissimilarity it was 
necessary to know whether thyroid function itaêLf was 
being affected by salicylate. This had in fact been 
investigated (Alexander & Johnson 1958) by means of 
radio-iodine tests, and the results indicated that over 
a period of up to eight weeks, no effect on thyroid as 
judged by radio-iodine uptake was evident.
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Chapter 2.
The Effect of Salicylate on Respiration.
Deepening of the breathing was one of the 
earliest of the clinical effects observed to follow 
treatment of acute rheumatism with salicylate 
(Langmead 1906, Madisson 1934) and after experimental 
administration of salicylate to man (Odin 1932,
Cochran 1952). It is now a well established effect and 
has more or less empirically been attributed to direct 
stimulation of the respiratory centre (Goodman &
Gilman, 1941). Indirect evidence supporting this view 
was put forward by Rapoport & Guest (1945), who 
demonstrated that salicylate induced an alkalosis in
monkeys and dogs, which was accompanied by
hyperventilation. A similar alkalosis accompanied by 
hyperventilation has been confirmed in man (Ryder et al 
1945, Parber et al 1949, and Reid et al 1952). The
reaction change of the blood was attributed by 
Rapoport & Guest (1945) to stimulation of the 
respiratory centre leading to the loss of excessive 
quantities of carbon dioxide from the lungs, which in
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turn gave rise to the alkalosis. The mechanism was 
analogous to the primary respiratory alkalosis induced 
by voluntary or hysterical overbreathing.
As a refinement to direct stimulation of 
the respiratory centre, Graham & Parker (1948) 
suggested that the action of salicylate was at vagal 
nerve endings, since they claimed that hyperventilation 
from intravenous injection of salicylate could be 
prevented by section of the vagus nerves in cats.
Cochran & Ramsay (1957), however, employing a more 
precise method of measuring pulmonary ventilation, could 
not confirm this claim. They found that section of 
the vagi did not prevent hyperventilation following 
injection of sodium salicylate in these animals.
While investigating respiratory gaseous 
exchanges in rabbits, Reid (1957) observed that 
increased output of carbon dioxide did in fact result 
from injection of sodium salicylate, but this was 
accompanied by a simultaneous and more pronounced 
increase in the oxygen consumption. These observations, 
in conjunction with the establishment of the drug as a 
peripheral metabolic stimulant (Sproull 1954), led to 
an alternative explanation of the respiratory stimulant 
action of salicylate. Reid (1957) concluded that the
“33—
drug was a primary metabolic stimulant and sijggested 
that the respiratory changes followed the increased 
oxygen requirement. In his interpretation the 
alkalosis was secondary to a relative diminution of 
carbon dioxide production attributable to stimulation 
of nitrogen katabolism, and confirmed by a fall in 
respiratory quotient.
Samet (1958) also suggested that the 
primary action of salicylate might be metabolic rather 
than respiratory as a result of investigations of the 
ventilatory response to carbon dioxide in patients with 
pulmonary emphysema. Several such patients were allowed 
to bregfche air containing differing amounts of carbon 
dioxide, and measurement of the minute volume was made 
before and after salicylate therapy. The same increase 
in ventilation was noted v/hether the patients breathed 
3^ or carbon dioxide, so that the slope of the 
ventilatory response curve during carbon dioxide 
inhalation was not increased. As a possible clinical 
application they decided that the depressed ventilatory 
response in pulmonary emphysema could not be reversed 
by salicylate, and made the suggestion that the increase 
in ventilation was secondary to the metabolic response 
of salicylate.
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The possibility that the respiratory 
stimulation of salicylate in man was secondary to the 
metabolic stimulation has been investigated directly 
by measuring increments in pulmonary ventilation and 
in oxygen consumption resulting from salicylate 
administration, and comparing these results with the 
findings already established under physiological 
conditions such as muscular exercise, when ventilation 
and oxygen consumption increase proportionately. This 
was first demonstrated in dogs by Zuntz (1897) and 
later by Slowtzoff (1903). A similar constancy of 
the ratio of ventilatory and metabolic increase during 
exercise was demonstrated in man by Asmussen et al 
(1943) in a detailed investigation carried out in one 
subject over a wide range of respiratory stimulation.
In a previous chapter the quantitative 
relation between serum salicylate concentration and 
oxygen consumption (and B.M.R.) was established. Prom
the tracings of oxygen consumption with the Benedict-
/
Roth apparatus, measurements of pulmonary ventilation 
were made. Tidal air was measured to the nearest 
50 ml. from the tracing and the respiratory rate was 
the mean of three or four individual minute counts;
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their product, the pulmonary ventilation in litres per 
minute (l./min.) was then expressed, like the 
metabolic stimulation as an increment of the patient * s 
pulmonary ventilation value when no salicylate was given. 
(Tables 2.2. & 23 ) ^ The same two main groups,
convalescents and myxoedematous patients were considered 
in turn.
The Relation between Pulmonary Ventilation and Metabolic 
Stimulation in Convalescent Patients.
Since both oxygen consumption and pulmonary 
ventilation values were available for each particular 
serum salicylate concentration over the range 0 to 60 
mg./lOO ml., it was possible to examine the 
relationship between them by graphing the 104 pairs 
of observations (Pig. 21, Table 22), and calculating 
the regression equation. The relation between the 
two variables, increment in pulmonary ventilation and 
increment in oxygen consumption, was not inconsistent 
with linear function, as evidenced by a correlation 
coefficient r = 0.37, (P 40.001). The scatter of the 
points was large, which may be accounted for partly 
by the accuracy with which measurement of tidal air
-36-
Fig. 21.
The relationship between pulmonary ventilation and
metabolic stimulation in the convalescent patients
during salicylate therapy.
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could be made from spirometer tracings. The equation 
of the regression was y = 0.22x + 1.0 where the abscissa 
represented the increment of oxygen consumption in 
cals./m /hr. and the ordinate the increment in 
pulmonary ventilation in l./min. It was concluded 
that, just as during exercise, a direct relationship 
exists between the respiratory and metabolic stimulation 
simultaneously induced in man by salicylate.
The Relation between Pulmonary Ventilation and Metabolic 
Stimulation in Myxoedematous Patients.
The relationship between metabolic stimulation 
and pulmonary ventilation induced by salicylate was 
studied in a similar way in the six myxoedematous 
patients (Nos. 8 to 15). A scatter diagram was 
drawn of the 82 pairs of observations made over the 
therapeutic dose range of salicylate. Again the 
relationship between pulmonary ventilation and oxygen 
consumption was not inconsistent with a linear function. 
The correlation coefficient was r = 0.49 (P<0.001) 
and the equation of the regression y = 0.25x + 0.35 
(Fig. 22 Table 23). The scatter of points was much 
less marked than with the convalescent rheumatic
-38-
Pig- 22.
The relationship between pulmonary ventilation and 
metabolic stimulation in the myxoedematous patients
during salicylate therapy.
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patients. It was concluded that the metabolic 
stimulation in myxoedema from the administration of 
salicylate was accompanied by a proportionate increase 
in pulmonary ventilation.
From inspection of the two scatter diagrams 
and the corresponding regression lines (Figs. 21 
and 22), it was observed that there was little difference 
either in slope or intercept of the two lines 
representing the ratios in the convalescent rheumatic 
and myxoedematous patients. This visual impression 
was confirmed by the following analysis.
Comparison of the slopes of the regression lines,
= 0.22x^ + 1.0, for the convalescents, and 
y2 = 0.25x2 + 0.55, for the myxoedematous, 
gave the variance of b^ (0.22) equal to 0.0016
and the variance of b2 (0.25) equal to 0.0063.
2
The variance of their difference, cr^ 2 = 0.0079*
This gives t = 0.78, which is less than t^ for 
182 degrees of freedom, 1.96. Thus there was no 
significant difference in slope between the two lines. 
Comparison of the intercepts made by the two regression 
lines gave for the expression (a) (Vide chapter 1), 
the value 0.66. This value is distributed as t. Tq 
for 183 degrees of freedom = 1.96. Therefore the
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calculated value of t < t^ indicating that there {
■ ‘I
was at the 5?^  level of significance no difference in ]
. ^
the intercepts made by the two lines. ;
Thus in both the convalescent and the ;
myxoedematous patients it was shown that the stimulation
of oxygen consumption by salicylate was accompanied 
by a proportionate increase in pulmonary ventilation.
It will be remembered that when the increase in 
metabolic stimulation was plotted against drug 
concentration, a steeper gradient was seen in the 
response of the convalescent group (b = 0.46, Fig. 10) 
than of the myxoedematous group (b = 0.29, Fig. 18,).
When however the drug concentration values are 
eliminated and only the respiratory and metabolic 
responses are considered, as in this chapter, the 
difference between the groups is no longer apparent.
(Fig. 23). It was thought therefore that although 
individuals may show a greater or lesser degree of 
metabolic stimulation, nevertheless the essential 
mechanism of action of salicylate is likely to be the 
same, since the ratio of the respiratory response to 
the metabolic response is almost identical in each case.
In attempting to identify the salicylate 
response with that of normal exercise, as was done in
—41—
Pig. 23.
Comparison of the ratio, pulmonary ventilation
metabolic stimulation during salicylate therapy
and during exercise.
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y = 0.126x + 0,2 
y = 0,25x + 0,35
y = 0.22x + 1.0
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dogs by Ramsay (1956), it was unfortunate that data 
for the exercise response in man was confined to 
meticulous observations in one individual (Asmussen 
et al 1945). Nevertheless the regression line 
calculated from his data was found to be 
y = 0.126x + 0*2 and did not materially differ from 
that obtained for salicylate in both convalescent and 
myxoedematous patients (Pig. 23). The inference 
is that increases in pulmonary ventilation to meet 
increased peripheral demand for oxygen are no 
different whether they occur as a result of 
administration of salicylate or voluntary exercise. 
There is therefore no need to invoke any explanation 
for respiratory stimulation by salicylate other than 
the physiological one associated with increased 
metabolic activity.
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Chapter 3.
Respiratory Caseous Exchange During Salicylate Therapy.
It has been demonstrated that salicylate 
produces both an increased metabolic rate and a 
proportionately increased pulmonary ventilation when 
administered in therapeutic doses to man. Speculation 
about the particular metabolites affected was made 
by Cochran (1952), who measured oxygen consumption 
and carbon dioxide output changes in a one-day 
experiment using intravenous salicylate, and then over 
several days using oral salicylate. Barbour &
Devenis (1919) had observed no change in respiratory 
quotient (R.Q.) after a single dose of aspirin, but 
Cochran demonstrated that if time were allowed for the 
salicylate concentration in the blood to reach at least 
30 to 40 mg./lOO ml., a distinct fall in R.Q. would 
result.
It was decided to reinvestigate the problem 
of the respiratory gaseous exchange in a few patients 
receiving aspirin and to pay particular attention to the 
food intake and appetite over the period, and thus
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eliminate R.Q. changes from starvation that might follow 
the early transient anorexia sometimes encountered in 
the first few days of full salicylate administration.
While it is recognised that if the R.Q. is 
to he taken as an indication of the food being oxidised 
at the time, it is best estimated over a lengthy 
period (Richardson 1929), nevertheless practical 
considerations made it necessary to confine the 
observations to serial and duplicate measurements, 
each lasting six minutes and the validity of this 
procedure was confirmed by simultaneous analysis over 
a longer period with a Haldane gas analyser. The 
results of this check are described later.
It had been observed (Reid et al 1950) that 
part of the metabolic changes which result from aspirin 
administration was an increased protein katabolism 
evidenced by the excretion of nitrogen in urine and 
faeces which exceeded the nitrogen intake in food.
Faecal nitrogen was small and failure to estimate it 
would not materially have altered this conclusion.
In this work, analysis of urine nitrogen alone was 
used in the limited nitrogen balance study which was 
to accompany the investigation of the respiratory 
exchange.
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Pour rheumatic patients (Cases 16 to 19) 
were studied. The group included a boy and a girl 
both aged 16 years and two women aged 29 and 39 
respectively. Each patient was given a well-balanced 
diet, with adequate calories and a known protein intake. 
Respiratory gaseous exchange and biochemical tests 
including urinary nitrogen output were carried out 
before and during administration of salicylate.
Nitrogen intake was calculated from the 
tables of McCance & Widdowson (1946) and total 
nitrogen output in the urine was estimated from 24-hour 
collection by the Kjeldahl method.
Oxygen consumption and carbon dioxide output 
were measured serially with a modified Knipping 
spirometer (Pig. 24) at 9 a.m. each day, two and a half 
hours after a light breakfast consisting of tea, 
fruit juice and cereal. Oxygen consumption was measured 
from the spirograph in the usual way; carbon dioxide 
was trapped in soda lime ("Durasorb") and weighed 
in the following manner. The Knipping apparatus was 
modified by replacing the usual carbon dioxide 
absorbant, a strong solution of KOH, by three "Quickfit" 
tubes connected in series (after Cameron 1957). Tubes
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Fig. 24»
Snipping circuit diagram
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Tubes 1, 3 contain CaCl2. 
Tube 2 contains soda-lime
indicates direction of gas flow.
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1 and 3 contained dessicants consisting of 8-14 mesh 
calcium chloride and a plug of magnesium perchlorate. 
Tube 2 contained "Durasorb" soda lime as the carbon 
dioxide absorbant. The tubes were plugged at either 
end with a little glass wool. The weight of carbon 
dioxide produced by the patient during the experimental 
period was measured by the increase in the second and 
third tubes weighed together. The efficiency of the 
circuit was demonstrated by the absence of an increase 
in weight in a second series of tubes inserted after 
the first.
Duplicate tracings, each of at least 6 minutes, 
were obtained. Simultaneous determination of expired 
gases collected with a KM sampler followed by analysis 
in a Haldane apparatus was performed in two of the 
patients and showed satisfactory agreement. Results 
of this comparison are shown in Table 24. Ten sets 
of observations were made by each method of analysis.
The mean oxygen consumption (Haldane) was 
250+13.3 ml./min. at s.t.p. and the mean oxygen 
consumption (Knipping) was 255+14.6 ml./min. at s.t.p. 
The mean carbon dioxide output (Haldane) was 
176+7.1 ml./min. at s.t.p. and the mean carbon dioxide 
output (Knipping) was 195+5.4 ml./min. at s.t.p.
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Table 24.
Comparison of Respiratory Quotients Measured by the 
Knipping and Haldane Methods.
Case
D.C.
Haldane Knipping
Date Oxygen Carbon 
Dioxide
H.Q. Oxygen Carbon 
Dioxide
H.Q.
5.5.56. 341 202 0.59 372 222 0.59
4.5.56. 260 169 0.65 247 175 0.71
7.5.56. 332 203 0.61 345 225 0.67
17.5.56. 251 191 0.76 257 188 0.73
J.McW. 24.4.56. 199 138 0.69 210 162 0.77
26.4.56. 166 125 0.75 248 179 0.72
28.5.56. 233 162 0.69 249 207 0.83
3.5.56. 301 208 0.69 271 200 0.74
11.5.56. 215 215 0.99 173 222 1.2
17.5.56. 202 152 0.75 173 167 0.97
Sum 2500 1763 2545 1947
Mean 250 176 255 195
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(Table 24). Such agreement between the methods 
indicated that the simpler modified Knipping 
technique was suitable.
Results of the Determination of Respiratory Quotient.
The respiratory gaseous exchange of the 
4 patients will be described and the implications of the 
findings discussed.
Patient J.MoW. (Case 16) was treated with 
aspirin for 18 days. The serum salicylate concentration 
rose to 74 mg./lOO ml. and the oxygen consumption 
from a pre-treatment value of 210 ml./min. to 
300 ml./min. at the peak level. The pre-treatment 
carbon dioxide output value was 162 ml./min. and this 
rose to 175 ml./min. at peak. She was maintained on 
a diet containing 63 g.protein and entered a phase 
of negative nitrogen balance after three days of 
aspirin treatment. It was noted the R.Q. rose 
dramatically when aspirin was discontinued and then 
regained its.normal value (about 0.8). A graphical 
representation of these changes ia shown in Fig. 25 
(Table 25 Appendix).
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Patient A.I. (case 17) was treated for 
27 days. The range of serum salicylate concentration 
varied from 7 to 62 mg./lOO ml. Prom a pre-treatment 
oxygen consumption of 287 ml./min., the value reached 
at the highest drug level was 390 ml./min. The 
carbon dioxide output rose from 252 to 315 ml./min.
This patient was maintained on a high protein intake 
of about 120 g. per day and was seen to be in negative 
nitrogen balance after four days treatment with 
aspirin. The results are expressed graphically in 
Pig. 26 (Table 26).
Patient P.Gr. (case 18) was given aspirin for 
a period of 50 days, during which the serum salicylate 
reached a concentration of up to 66 mg./lOO ml. The 
pre-treatment oxygen consumption was 253 ml./min. and 
rose to 345 ml./min. at the peak level. The rise in 
carbon dioxide output was from 214 ml./min. before 
treatment to 225 ml./min. at peak. On a diet in which 
the protein intake was maintained at about 50 g. per 
day this patient entered a phase of negative nitrogen 
balance after about four days of aspirin therapy.
The results are shown graphically in Pig. 27 (Table 27).
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Fig. 26.
Effect of salicylate on respiratory quotient
and nitrogen balance : case 17.
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Patient M.McN. (case 19) received salicylate 
for 15 days. The highest serum concentration of the 
drug reached was 59 mg./lOO ml. Her pre-treatment 
oxygen consumption was 167 ml./min. and this rose to 
255 ml./min. on treatment. The change in carbon 
dioxide output was from 148 to 178 ml./min.
Maintained on a balanced diet containing 65 g. protein, 
she entered a phase of negative nitrogen balance 
after about four days of aspirin therapy. A graphical 
representation of the results are given in Fig. 28.
From inspection of the data of these four 
patients, it was evident that while both oxygen and 
carbon dioxide were increased during aspirin therapy, 
nevertheless the increase in carbon dioxide output was 
a disproportionate one, with the result that the R.Q. 
tended to fall. Indeed a definite pattern of R.Q. 
change was observed. A sharp fall in R.Q. occurred 
when the serum salicylate concentration reached its 
first peak level. In case 16, the R.Q. fell from 
0.77 before salicylate commenced to 0.46 when the 
blood concentration had reached 55 mg./lOO ml., and 
again to 0.58 at 74 mg./lOO ml.; in case 17, the 
R.Q. fell from 0.88 before treatment to 0.59 at 
47 mg./lOO ml. salicylate; in case 18, the R.Q. fell
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Pig. 28.
Effect of salicylate on respiratory quotient
and nitrogen balance ; case 19*
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from 0.85 before treatment to 0.60 at 55 mg./lOO ml. 
salicylate; in case 19» the R.Q. fell from 0.89 
before to 0.62 at 52 mg./lOO ml. and again to 0.58 
at 55 mg./lOO ml. salicylate. This fall coincided 
with the point at which the patient began to enter 
a negative nitrogen balance. On maintaining the 
salicylate at therapeutic levels, the R.Q. rose 
slightly although still below the pre-treatment 
figure. Any subsequent near-toxic dose was accompanied 
by another sharp fall in R.Q. (cases 16 and 19).
On discontinuing the drug, the R.Q. rose to more than 
1.0 and after a few days, it returned along with the 
B.M.R. to normal.
Inspection of the actual R.Q. values before 
and at peak salicylate concentrations permitted of a 
more accurate assessment of these changes. A graph 
of the four pre-treatment values of oxygen consumption 
and carbon dioxide output-wei^ drawn (Pig. 29). The 
equation of the line representing these points was 
y = 1.06x +23. The six pairs of values for oxygen 
and carbon dioxide production at the peak salicylate 
concentrations were similarly drawn. The equation 
representing these points was y = 1.35% + 78 (Pig.29). 
As will be seen, the respiratory response of the four
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before and during salicylate therapy.
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patients before salicylate therapy was perceptibly 
different from that observed after salicylate had been 
administered.
The regression equations of the two lines 
were accordingly analysed for difference in slope or 
intercept :
Equation of the "pre-treatment'* regression 
y^ = 1.06x^ + 25.
Equation of the regression resulting during salicylate 
therapy
y2 = 1«33x 2 + 78.
Analysis of variance of the regression coefficients 
b^ = 1,06 and bg = 1.33 gave
Weighted average residual variance = 20.28.
2
Variance of their difference = 0.047 = 0*^ 2
Calculated t = (b^ - ^2^/^12 “
to Q5 for 10 degrees of freedom = 2.23.
The difference in slope is not evident at this level 
of significance.
The intercepts of the two lines were then
compared.
Expression (a) (vide chapter 1) = 4.6 and was 
distributed as t. For 7 degrees of freedom, this
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value of t was significant at the 3f<> level.
Prom the detailed study of the effect of 
aspirin on the respiratory quotients of four 
patients further evidence for a metabolic action of the 
drug has been presented. The R.Q. fell markedly as 
soon as therapeutic serum salicylate levels had been 
established and remained subnormal until the drug was 
discontinued. Prom the value of the patients*
R.Q.*8 during treatment, it is suggested that the 
normal metabolic pathways have been affected. The 
increased energy requirement, as evidenced by an 
increased B.M.R. may in part be derived from the 
combustion of fat in preference to the physiological 
breakdown of carbohydrate. Y/hether this is caused 
however by interference with one of the intermediate 
breakdown products in carbohydrate metabolism or 
merely as a response to the suddenly increased need 
for oxygen is not known.
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Chapter 4.
Comparison of the Metabolic Stimulating Effects
of Salicylate and Einitrophenol.
Investigation of the stimulant action of 
salicylate and support for the hypothesis of a 
primary metabolic action recalled the properties of 
another well-known metabolic stimulant, 2:4- 
dinitrophenol (ENP). Since its relative toxicity 
has made EEP unsuitable for large-scale investigation 
in man, much of the evidence of its mode of action 
has been gained from work on animals and tissue 
slices. A short review of the literature on the 
drug, so far as it is relevant^ to the stimulation 
of metabolism and respiration, will be presented and 
will be followed by description of a carefully 
controlled study in man and animals carried out to 
compare the actions of salicylate and ENP.
In 1894> Gribbs & Reichert noticed that 
oral administration of ERP to dogs stimulated 
respiration and raised the body temperature. Walko 
(1901), experimenting with rabbits, and Sander with
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mice, confirmed this increase in respiration.
Heymans (1934) noted that the ERP-induced hyperthermia 
in pigeons was closely associated with an increase in 
oxygen consumption. The first accounts of the 
pharmacodynamic action of ENP appeared in 1932.
Both Magne et al (1932), Hall et al (1933) and 
Gragliani & Tainter (1936) showed that in dogs 
EHP caused both an increase in oxygen consumption 
and in respiration. Magne et al (1932) further 
claimed that its effect was not of central origin 
since the hyperpyrexia which accompanied this 
increase in metabolism was not affected by 
anaesthetics. They concluded that respiratory 
stimulation with ENP was a direct consequence of 
increased oxygen utilisation by cells. In support 
of this claim of a peripheral action, Alwall &
Scheff-Pfeifer (1936) reported that oxygen metabolism 
was increased in the isolated dog leg, and Eodds & 
Greville (1933) reported increased respiration of 
mammalian tissue slices by ENP. More recently 
Sproull (1954) has shown that both salicylate and ENP 
stimulate oxygen consumption of tissue slices and 
Reid (1957) has shown that the action of ENP in rabbits 
resembled that of salicylate, in that both drugs
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stimulate oxygen consumption which results in 
hyperpyrexia and even death if the doses are large 
enough. The pharmacological similarity between ENP 
and salicylate thus extends to the realm of toxicology.
It is realised now that the metabolic action 
of ENP is not a clear-cut one of stimulation and may 
depend on substrate (Terner 1952), on environmental 
temperature (Magne et al 1932, Tainter 1934) and on 
the drug concentration (Plantefol 1933> Sproull 1954), 
but its importance, in man at least was first 
appreciated in connexion with its metabolic stimulating 
properties. Tainter et al (1933)> Eunlop (1934) and 
Masserman & Goldsmith (1934) had all drawn attention 
to its possible use as a weight reducer, but its 
indiscriminate use was found to produce hyperpnoea and 
fever (Geiger 1933)> and prolonged and massive dosage 
was later suspected of having caused irreversible 
complications such as cataract, though sole 
responsibility for this was questioned (Eally 1936, 
Eavis 1937 and Lindahl 1940).
Short-term studies of the metabolic stimulant 
effect of ENP primarily undertaken to control ENP 
administration in a study of its action in myxoedema.
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diabetes mellitus and other conditions provided 
data for a comparison with salicylate.
The first group of patients considered 
consisted of four middle-aged diabetics in whom the 
effect on blood sugar was being studied, and one 
patient with hypercholesterolaemia (cases 20 to 24). 
All had resting B.M.RJs within normal limits when 
no drug was given, and were afebrile throughout the 
period of investigation.
The second group comprised three patients 
with myxoedema in whom the effect on the subnormal 
metabolism and hypercholesterolaemia was being 
investigated (cases 25 to 27). At no time during 
treatment did adverse symptoms or pyrexia develop.
Metabolic and respiratory investigations 
were made in exactly the same manner as in the 
salicylate studies and the plasma concentration of 
ENP was estimated by the method of Parker (1949) to 
allow concentrâtion-response studies to be undertaken 
Plasma ENP Concentration and the Metabolic Rate in 
the Eiabetic Group. Measurement of the oxygen 
consumption and simultaneous estimation of plasma 
ENP were made during two weeks of ENP administration 
to each of the patients in the first group
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(cases 20 to 24). Linear correlation was established 
in each case between concentration and response.
The regression lines which represented the pairs of 
observations were constructed and were drawn 
together in Pig. 30. A summary of the clinical data 
of the individual patients is given in Table 29.
A summary of the regression data is given in Table 30.
Conforming to earlier practice, each 
value of the metabolic rate was expressed as the 
increment of oxygen consumption above the patient's 
resting value when no treatment was given. The 
forty-five points were plotted on one graph 
(Pig. 31> Table 31, Appendix), covering a plasma 
ENP concentration of 6 to 51 mg./l. Linear 
correlation was established, the correlation 
coefficient r = 0.78, with a high degree of 
significance (P < 0.001), and 955^  confidence limits 
of the line were +5.98. The equation of the 
regression was y = 0.27x + 3.3 (Pig. 31).
Plasma Concentration of ENP and Metabolic Stimulation 
in Myxoedema. The relationship between drug
concentration and metabolic rate in the myxoedematous 
patients was found to be linearly correlated in each 
case and the three regression lines were drawn (Pig.32).
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Composite regression line : diabetic patients
cases 20 to 24*
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A summary of the clinical data of the individual 
patients are given in Table 29> and of the regression 
data in Table 50 (Appendix).
The composite regression curve constructed 
from the thirty-seven pairs of observations gave a 
linear correlation v/ith a coefficient r = 0.86 and 
the 95^ confidence limits of the line +5.1# The 
equation representing this regression was 
y = 0.29X - 2.0 (Fig. 35, Table 32).
The impression formed from visual 
inspection of the regression lines of the diabetic 
and myxoedematous groups (Figs. 31 and 35) was that 
while the intercepts were slightly different, the 
slopes were similar. This impression was tested 
by statistical analysis.
The slopes of the two lines represented by 
y^ = 0.27x^ + 3.5 for the diabetics, 
and y2 = 0.29%2 “ 2.0 for the myxoedematous, 
were examined by comparing their regression coefficients 
b^ and bg.
The variance of b^ = 0.00089 and of bg = 0.00099,
2
The variance of their difference 0^2 == 0.0018.
The value of t = (b^ - ^2^/^12 “ 0.465. For
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Composite regression line : myxoedematous patients
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and 78 degrees of freedom, the estimate of t = 1.99. 
Thus the calculated t <(tQ indicating that there 
was no significant difference between the gradients 
of the lines.
Comparison of the intercepts of the two 
regression lines gave, for the expression
______  ex., —
7  -L+-L
^  Hi n.
a value of 2.73. This is greater than the estimated 
value of tg for N - 3 i.e. 79 degrees of freedom, 
1.99. It was concluded that there was a significant 
difference in intercept between the two lines.
In contrast to the findings of patients 
whose metabolism had been stimulated with salicylate, 
it was observed that DNP stimulated both myxoedematous 
and patients with normal thyroid function to the same 
degree, although in both cases, as was expected, a 
different intercept was observed probably due to the 
lower initial starting level of the hypothyroid 
subjects.
The relation between oxygen consumption 
and pulmonary ventilation resulting from DNP 
administration was next investigated using methods
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similar to those used in the salicylate studies*
DNP and Pulmonary Ventilation and Metabolic Stimulation
in the Diabetic Group $ The same five patients who
had taken part in the study of the metabolic response
to PNP were reconsidered to evaluate the respiratory
response. Measurement of pulmonary ventilation was
made from the tracings obtained in the estimation
of oxygen consumption. Since each particular
respiratory estimation was made at the same plasma
concentration of the drug as the oxygen consumption
values, pulmonary ventilation and metabolic
stimulation were compared directly by plotting the
34-
pairs of observations. Figure^represents the scatter 
diagram formed from the 45 pairs of observations in 
the diabetics. A linear correlation was established 
between the increment in pulmonary ventilation (y) 
and the increment in oxygen consumption (x). The 
correlation coefficient r = 0.56 (p = 0.01) and 
the eq.uation of the regression was y = 0.126x + 0.72 
(Pig. 54, Table 55). It was thus shown that the 
administration of DNP to man resulted in a stimulation 
of metabolism which was associated with a corresponding 
increase in pulmonary ventilation.
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The relationship between pulmonary ventilation and
metabolic stimulation in the diabetic patients
during DNP administration.
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DNP and Pulmonary Ventilation and Metabolic Stimulation 
in the Myxoedematous Group# The increase in 
pulmonary ventilation shown by the three myxoedematous 
patients while they were receiving DNP was investigated 
in the same manner and the results were compared with 
the simultaneous estimates of oxygen consumption.
A scatter diagram consisting of 57 pairs 
of observations is shown in Pig. 55. Analysis 
suggested a linear correlation between the increase 
in metabolic stimulation (x) and the increase in 
pulmonary ventilation (y). The correlation coefficient 
r = 0.559 (0*05>P< 0*02), and the equation of the 
regression was y = 0.15% + 0.98 (Pig# 55 Table 54)#
It was thus shown that during administration 
of DNP to the myxoedematous patient there was a 
proportional increase between increase in oxygen 
consumption and increase in pulmonary ventilation.
Inspection of the lines representing this 
ratio in the diabetic and in the myxoedematous patient 
appeared to be roughly similar in slope, and an 
analysis of both gradient and intercept was done to 
establish the exact relationship.
Comparison of the slopes of the lines,
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Fig. 35.
The relationship between pulmonary ventilation and 
metabolic stimulation in the myxoedematous patients
during DNP administration.
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~ 0.126x^ + 0.72, for the diabetic group, and 
72 = 0.15X2 + 0.98, for the myxoedematous group, gave 
The variance of b^ = 0.0018 and of b2 = 0.0022,
The variance of their difference cr^ 2 = 0.0040.
The value of t = b^ - For 78 degrees
of freedom, the estimated value of t^ = 1.99#
Thus the calculated t was less than t^ q ,^ indicating 
that there was no significant difference in the slopes 
of the two lines.
Comparison of the intercepts of the two 
regression lines, gave by means of the above formula,
( (a) ) the value of 1.65> in the t distribution.
This was less than the value of t^ for 79 degrees 
of freedom 1.99. It was concluded that there was no 
significant difference between the intercepts formed 
by the two regressions.
The impression formed from inspection of the 
diagrams. Figs. 34 and 35» was thus confirmed: the
ratio between metabolic stimulation and pulmonary 
ventilation after DNP was the same. Fig. 36 shows 
the representation of the DNP-induced pulmonary 
ventilation/oxygen consumption ratio compared with the 
Asmussen (1943) representation of the results of 
voluntary exercise in one normal man. Inspection
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Fig. 36,
Comparison of the ratio, pulmonary ventilation :
metabolic stimulation during DNP administration
and during exercise.
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of the diagram showed that the three lines were 
similar in both slope and intercept, which supports 
the contention that respiratory stimulation in man 
induced by DNP was similar to that induced by exercise 
stimulus in dogs (Ramsay 1956).
Summary of the Comparison of the Pulmonary Ventilation/ 
Metabolic Stimulation Ratio with Salicylate and
Dinitrophenol.
The metabolic and respiratory stimulant 
action of both salicylate and DNP was studied in four 
main groups of patients. In order to compare the 
effects of the two drugs, the relationship between the 
ventilatory and metabolic responses was investigated 
in each group, and the following equations were 
derived:
y = 0.22x + 1.0 for the convalescents with salicylate 
administration,
y = 0.25x + 0*35 for the myxoedematous with salicylate 
administration,
y = 0.126x + 0*72, for the diabetics with DNP 
administration, and y = 0.15x + 0*98 for the 
myxoedematous with DNP administration.
It was concluded that there was little 
difference between the metabolic-respiratory response
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to salicylate , and to M P .  Furthermore, when 
these equations were compared with the equation 
derived from data from the results of exercise 
(Asmussen 1943), the results were not inconsistent 
with the conclusion that respiratory stimulation 
following increased oxygen consumption from either 
DNP or salicylate does not differ from the physiological 
exercise stimulus.
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Chapter 5.
Compariaon of the Grl.ycogenol.ytic Effects of 
Salicylate and 2 ;4-dinitrophenol.
Both salicylate and 2:4-dinitrophenol have 
been shown to stimulate oxygen consumption of the 
whole animal and of tissue slices. Similarity in 
their effects on the ratio of increased oxygen 
consumption to increased pulmonary ventilation, and 
on the R.Q. in man has alreadybeen described. 
Furthermore, Brody (1956) showed that salicylate 
stimulated the oxygen consumption of mitochondria 
without a commensurate effect on the uptake of organic 
phosphate. This dissociation of oxidation and 
phosphorylation had previously led Loomis and 
lipmann (1948) to introduce the concept of the 
uncoupling of oxidative phosphorylation in explanation 
of the action of dinitrophenol. Other similarities 
between the drugs included the initial depletion of 
liver and muscle glycogen after administration of a 
large single dose of either salicylate (Lutwak-Mann 
1942, Smith 1952 and Sproull 1954) or of DNP (Barnes
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(1953).
Barnes (1953) had also shown that prolonged 
administration of DNP to rats had a different effect 
on liver glycogen than a single large dose: a single
dose depleted liver glycogen, whereas prolonged 
administration increased it. It was therefore 
decided to find out whether salicylate also possessed 
this paradoxical action and to compare it with DNP.
Wistar rats were chosen as suitable 
experimental animals and the drugs were given for 
ten days. The rats were weighed and oxygen 
consumption was measured at intervals throughout the 
period of investigation and again just before 
sacrifice. This was done by placing the rats in groups 
of four in a desiccator divided into four compartments. 
The desiccator was connected to the modified Knipping 
spirometer previously described (Pig. 24), which 
circulated oxygen and removed carbon dioxide with 
soda lime absorbers. At the end of ten days, the 
rats were sacrificed by guillotine without anaesthetic. 
Liver samples were excised for the estimation of 
glycogen content by the method of Good et al (1933). 
Blood samples were collected in oxalate-fluoride 
tubes from the great vessels at the neck for estimation
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of drug concentration (salicylate by Trinder’s 
1954 method; M P  by Parker's 1949 method), and also 
for blood sugar estimation by the Lehmann & Silk 
(1952) modification of the Polin & Wu method.
Salicylate and DNP had to be administered 
to the rats in such a way that an effective blood 
concentration was maintained throughout the twenty-four 
hours of the day so that the effect of the drugs would 
be continuous. The best procedure to achieve this was 
to mix the substances with ordinary powdered M.R.C. 
"Diet 41" and feed the rats ad lib. A preliminary 
trial of this method was made and a group of sixteen 
rats (Group I) was fed with ordinary diet in powdered 
form until a steady gain in weight was achieved - about 
three weeks. Then eight were changed to a mixture 
containing 5% sodium salicylate, and eight to one 
containing 0.1^ DNP. After five days, i.e. half way 
through the proposed experimental period, the animals 
were sacrificed and blood concentrations estimated at 
six-hourly intervals throughout one day.
The results of this feeding trial (Table 35) 
show that the mean plasma salicylate concentration 
obtained was 34.4 mg./lOO ml. over a range of 26 to 
45 mg./lOO ml., and the mean plasma DNP concentration
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Table 35. 
Sixteen Rata - Group I
Plasma Plasma
Salicylate DNP
Time Rat No. mg./lOO ml. Rat No. mg./l.
3 p.m. 1 32 9 40
2 26 10 17
9 p.m. 3 26 11 15
4 30 12 23
3 a.m. 5 44 13 51
6 40 14 45
9 a.m. 7 32 15 37
8 45 16 —
Drug concentrations in the blood of sixteen
estimated at intervals throughout 24 hours.
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32.6 mg./l. over a range of 15 to 51 mg./l. This 
method of administering the drugs was therefore 
considered suitable for the main investigation.
Two further groups of sixteen rats 
(Groups II and III) were then caged in pairs and allowed 
to accustom themselves to ordinary powdered diet for 
one month. A normal weight gain was achieved after 
a slight initial loss due to changed conditions.
Several measurements of the rats* oxygen consumption 
were made to establish the mean untreated basal 
reading. Eight animals from each group were then fed 
on the 5% salicylate mixture or on the 0.1^ DNP 
mixture. The remaining eight in each group acted as 
controls and were left untreated. Special feeding was 
continued for ten days, when both treated and untreated 
animals were sacrificed. Liver and blood samples were 
taken immediately after death.
The mean blood concentrations of the drug 
obtained from the salicylate-treated animals (Group II) 
at sacrifice varied from 15 to 41 mg./lOO ml., the 
mean being 32.1 mg./lOO ml., which was similar to that 
obtained in the trial Group I (mean 34.4 mg./lOO ml., 
range 26 to 45 mg./lOO ml.). The blood DNP 
concentrations of the other eight animals (Group III)
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ranged from 18 to 31 mg./l., the mean being 24.9 mg./l. 
(of. the trial DNP group with a mean of 32.6 mg./l. 
and a range of 15 to 51 mg./l.).
The blood levels of salicylate and DNP were 
of the same order as those used in their therapeutic 
applications and the effect of these concentrations 
on rat liver glycogen and blood sugar, oxygen consumption 
and body weight will now be described.
Prolonged Salicylate Administration. Continued 
administration of sodium salicylate to normal rats 
for ten days produced a marked decrease in liver 
glycogen compared with that of the controls. The 
mean value of the eight salicylate-treated rats was 
2.05 + 0.64?^, while that of the untreated rats was 
5.84 + 2.15^. Comparison of the results by 
Student’s t-test showed the difference observed 
to be significant (t = 3.88 p >.01) (Table 36).
No change was noted between the blood sugar 
concentrations of the treated rats, 102.3 + 13.5 mg./
100 ml., and that of the controls, 101.6 + 3.8 mg./
100 ml. Owing to the method of administering the 
drug, fasting levels were not available, but from the 
results obtained it was possible to conclude that there 
was no material difference between the groups.(Table 36).
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Table 36.
The Effect of Salicylate on Liver Glycogen and
Blood Sugar*
No. of Blood Sugar* Liver Glycogen^ 
Group II Rats mg./lOO ml. g./lOO g.
Treated 8 102.3+13.5 2.05+0.64
Untreated 8 101.6+ 3.8 5.84+2.13
* Mean values + standard error are given for 
liver glycogen and blood sugar.
+ Statistical significance of the difference 
between the results for the treated and 
untreated groups; t = 3.88, P > 0.01.
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The salicylate-fed animals began treatment 
with a mean body weight of 357 g. At the end of 
ten days it had fallen to 307 g. i.e. a decrease of 
14?^ . Although it was not possible to keep the rats 
in metabolic cages, no obvious decrease in food intake 
was noted: on the contrary, the food containers of
the treated group required more frequent refilling 
than those of the controls. Change in body weight 
of the control group was negligible - a decrease of 
only Ifof from 388 g. to 384 g. (Table 37).
Salicylate produced an increase in oxygen 
consumption throughout the experimental period 
(Table 37). After five days of treatment, the 
salicylate-fed group showed an increase of 69^, and 
immediately before the animals were sacrificed, an 
increase of 50^, compared with an increase of 5^ 
and 11^ respectively in the controls. All these 
figures were expressed with respect to the pre-treatment 
values for the particular group.
Prolonged DNP Administration. After ten days of DNP 
administration the mean liver glycogen of the treated 
group was 6.94 + 2.78^ and that of the untreated group 
6.87 ±  2.63^, and there was no significant difference 
between these values when examined by Student’s t-test. 
(Table 38). In this DNP differed from salicylate
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Table 38.
The Effect of 2;4-Dinitrophenol on Liver Glycogen and
Blood Glucose.
Liver Glycogen 
Blood Sugar* g./lOO g. 
Group III No. of Rats mg./l00 ml. wet weight
Treated 8 93.2+8.8 6.94+2.78
Untreated 8 103.0+8.3 6.87+2.63
* Mean values + standard error are given for liver 
glycogen and blood sugar.
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which depleted liver glycogen.
There was no difference between the mean 
blood sugar concentration of the treated group,
95.2 + 8.8 mg./lOO ml. and that of the untreated 
group, 103.0 + 8.3 mg./lOO ml. at sacrifice 
(Table 38).
The mean body weights of the rats given DNP 
decreased by only 45^  over the experimental period, 
falling from a mean of 201 g. to 193 g.; the control 
group however showed a slight increase from 201 g. 
to 205 g. i.e. 2^ (Table 39).
The treated rats showed an increase in 
oxygen consumption amounting to 435^  after 5 days and 
58^ after 10 days. This compared with increases of only 
Qfo and 11^ respectively in the untreated group 
(Table 39).
Summary of the Results.
These results showed that oral administration 
of the drugs was practical and that blood concentrations 
of the same order as those used therapeutically were 
maintained over the whole day. Administered over a 
period of ten days, sodium salicylate caused an increase 
in oxygen consumption, depletion of liver glycogen,
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loss in body weight and no change in non-fasting 
blood sugar concentration* For the same order of 
metabolic stimulation, M P  produced a slight weight 
loss, and no change in liver glycogen content or 
blood sugar concentration. It was concluded that the 
effects of prolonged administration of salicylate and 
DNP on liver glycogen of rats were not identical.
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Discussion.
In the foregoing chapters the study of the 
respiratory and metabolic effects of salicylate and 
their comparison with dinitrophenol (DNP) has 
provided a quantitative analysis of some of the well- 
known results of salicylate therapy.
Although dose-response curves were constructed 
for the effect of salicylate on the metabolic rate of 
tissue slices (Sproull 1954) and rabbits (Reid 1957), 
no detailed investigation of the response in man had 
been derived. Qualitative stimulation of metabolism 
had been established by Cochran (1952) but the effect 
of aspirin on the oxygen consumption of man has been 
quantitatively studied only in this work and it has 
been shown that oxygen consumption and serum salicylate 
concentration are directly related to one another over 
the complete therapeutic range of concentration. The 
first group of patients examined in this way were 
convalescent rheumatics and were normal, clinically and 
biochemically, each patient having already received 
aspirin over a period of at least four weeks previously
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in the treatment of the disease.
When concentration-response curves of these 
patients were compared with those of a group of 
hypothyroid patients, a significant difference was 
found. The main difference between the patients was 
obviously the function of the thyroid gland in both 
groups and the possibility was considered that this 
was connected with the quantitative difference 
observed. It has been shown however (Alexander 
& Johnson 1958) that in both euthyroid and 
hypothyroid individuals treated with aspirin for at 
least as long as the patients under consideration here, 
no alteration in thyroid function, as measured by
1 * 5 1
I uptake by the thyroid gland, was detected.
Another possibility, that some interaction 
between aspirin and circulating thyroxine occurred, 
was suggested because of the lesser degree of stimulation 
seen in the myxoedematous group. A specific 
experiment to test this hypothesis has not however 
been performed.
Salicylate increases oxygen consumption and 
stimulates respiration to the extent of causing 
hyperventilation. The relation between the increased 
metabolic rate and the simultaneous increase in
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pulmonary ventilation was examined in the same groups 
of patients, and the ratio between the two responses 
was found to be similar in each group, and also 
similar to that obtained during muscular exercise 
(Asmussen et al 1943). This indicated that the action 
of therapeutic doses of salicylate was in no way 
different from the exercise stimulus in these respects 
and that respiratory stimulation was a direct result 
of metabolic stimulation.
Comparison with another recognised metabolic 
stimulant, dinitrophenol, was made. In studying the 
respiratory and metabolic effects of DNP in man, it 
was found that while the increase in oxygen consumption 
of all the subjects was the same, irrespective of 
thyroid function (this in contrast to the salicylate 
effect), nevertheless the ratio of oxygen consumption 
to pulmonary ventilation was again indistinguishable 
from that resulting from stimulation by exercise.
This was in agreement with the results obtained by 
Ramsay (1957) experimenting with rats under DNP 
administration.
Among the metabolic effects mentioned in 
the preliminary reports on increased oxygen consumption 
in man (Cochran 1952), a lowering of the respiratory
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quotient after single doses of salicylate was noted. 
This aspect of the work was re-examined in four 
patients on whom balance studies were being conducted.
A prolonged depression of the R.Q. was noted, which 
commenced when the patient’s excessive excretion of 
nitrogen caused him to enter a phase of negative 
balance. This confirmed the suggestion that the prime 
effect of salicylate was of metabolic origin, and from 
the low levels of the R.Q. one may reasonably be led to 
the postulate that there is a preferential breakdown 
of fat, rather than carbohydrate, to meet the energy 
requirements.
Finally, the possible interference in the 
metabolism of carbohydrate was investigated on a 
limited scale by assessing the effect of prolonged 
administration of salicylate to rats. Again 
comparison was made with DNP by carrying out an 
identical experiment with that drug* Y/hereas it had 
been shown that single doses of both DNP (Barnes 1953) 
and salicylate (Smith 1954) to rats caused an Initial 
depletion in the normal liver glycogen which was 
followed by a return to normal after twenty-four hours * 
in these experiments the depression was seen to 
persist with the continued administration of salicylate
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but not with DNP. The animals in both treated groups 
lost weight when compared with the control sibling 
rats, but the amount lost by the salicylate-fed group 
was considerably greater*
Thus it has been shown that many of the 
respiratory effects of salicylate may be likened to 
those of another metabolic stimulant, dinitrophenol, 
but that their action is not wholly identical* The 
prime action of salicylate would seem to be metabolic 
in origin and the purely respiratory results which 
occur to be sequential rather than causal* The many 
facets of salicylate action still remain relatively 
unconnected and it may well'be that the action itself 
is a complex one, altered by certain other 
physiological or pathological conditions.
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Summary.
I. The effect of salicylate on the basal metabolic
rate, the pulmonary ventilation and the respiratory 
quotient was quantitatively studied in man over 
the therapeutic dose range.
(a) A linear correlation was established between the 
serum salicylate concentration and the basal 
metabolic rate in the afebrile convalescent,
the diabetic and the myxoedematous subject. The 
response of the myxoedematous patients was not 
the same as that of the convalescent, but no 
alteration in thyroid function was detected.
(b) Increased oxygen consumption due to salicylate was 
accompanied by a commensurate increase in pulmonary 
ventilation and the ratio of these responses was 
similar to the exercise stimulus.
(c) The respiratory quotient was depressed over a 
considerable period of salicylate administration, 
the first peak coinciding with the onset of 
nitrogen katabolism.
(d) Studies in the rat showed that salicylate 
sufficient to stimulate metabolism by fifty per 
cent interfered with normal carbohydrate metabolism, 
inducing depletion of liver glycogen and loss in 
body weight.
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II. Comparative metabolic and respiratory studies 
were carried out with 2 :4-dinitrophenol in 
diabetic and myxoedematous patients, and 
comparison of the glycogenolytic action was 
studied in the rat.
(a) The metabolic rate was linearly correlated 
with the plasma M P  concentration. Unlike 
salicylate, DNP induced the same response in 
all subjects regardless of thyroid function.
(b) Increased oxygen consumption due to DNP was 
accompanied by a commensurate increase in 
pulmonary ventilation and the ratio of these 
responses was similar to the exercise stimulus.
(c) Studies in the rat showed that DNP differed 
from salicylate in that, though the same degree 
of metabolic stimulation was induced, no effect 
on the liver glycogen was detected and the loss 
in body weight was less marked.
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Table 1.
Comparison of dose-response and concentration-responae
curves* (Fig. 1).
°2
ml./mln. B.M.E. Dose Cone
Date at N.I.P. fo Normal gr./day mg./I00
11.7.55. 155 83 50 18
12.7.55. 173 94 55 21
13.7.55. 176 95 62.5 31
14.7.55. 174 94 62.5 31
15.7.55. 190 102 65 36
16.7.55. 199 107 65 34
20.7.55. 182 98 55 23
21.7.55. 188 102 75 30
22.7.55. 188 102 77.5 36
23.7.55. 218 117 77.5 44
25.7.55. 205 111 82.5 43
Data of the Eegre ssions.
Dose-response Cone.-response
n = 11 n = 11
r = 0.79 P<0.01 r = 0.88, P <0.001
y = 0.68% 4- 55.25 y = 0.98% + 69.5
- 5*95 ^ =5 4*64
t<fr = +13.27 t < T r =  +10.49
- 101-
Table 3*
Olinical data of the individuals in the salicylate
investigation.
Case Name Diagnosis Sex
Age
yrs. m2
JLM . . XVJ. . XI. .
2
cals/m /hr
1 G.W. Rheumatic fever M 25 2.04 37.1
2 S.H. Rheumatic fever P 24 1.43 33.9
3 R.C. Rheumatic fever M 25 1.70 37.6
4 A.W. Rheumatic fever M 18 1.62 39.2
5 O.MoC. Rheumatic fever P 37 1.40 34.0
6 J.McW. Rheumatic fever P 16 1.44 36.0
7 M.Gr. Rheumatic fever P 14 1.36 37.8
8 M.McM. Myxoedema M 52 1.80 33.8
9 A,McD. Myxoedema P 65 1.74 31.0
10 I.McG. Myxoedema P 72 1.84 30.7
11 P.P. Myxoedema P 72 1.64 30.7
12 M.B. Myxoedema P 43 1.56 32.5
13 P.A. Myxoedema P 52 1.72 31.9
14 M.G. Obesity P 67 1.73 31.0
15 W.B. Diabetes mellitus M 58 1.88 33.4
+S.A. = surface area calculated from weight and 
standing height (Du Bois).
* N.B.M.E. = normal basal metabolic rate.
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Fig. 2.
Concentration-reaponse curve : case 1.
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Table 4.
Basal metabolic rates and serum salicylate
concentrations: case 1 (Pig. 2).
°2
ml ./min. B.M.E. Ser. Sal.
Date at N.T.P . fo Normal mg./lOO ml.
1.12.55. 314 120 24
1.12.55. 317 121 27
2.12.55. 319 122 29
3.12.55. 324 124 33
5.12.55. 313 120 31
6.12.55. 297 114 26
6.12.55. 305 118 32
7.12.55. 326 125 35
7.12.55. 325 125 37
9.12.55. 322 123 40
9.12.55. 328 126 40
10.12.55. 313 120 35
11.12.55. 331 127 42
13.12.55. 322 123 35
14.12.55. 329 126 38
14.12.55. 338 130 44
15.12.55. 343 132 50
16.12.55. 286 110 15
19.12.55. 268 103 0
20.12.55. 260 99 0
Data of the Eegres Sion.
n = 18
r = 0.91» P'<0.001
y = 0.59x + 102.5
= 2.26 
bSr - +4.79.
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Fig. 3.
Concentration-response curve : case 2,
B.M.R,
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Table 5.
Basal metabolic rates and serum salicylate
concentrations: case 2 (Pig. 3).
°2
ml./mln. B.M.E. Ser. 8
Date at N.T.P. io Normal mg./lOO
20.6.56. 203 122 43
22.6.56. 192 115 44
22.6.56. 189 114 47
25.6.56. 186 112 46
25.6.56. 173 104 33
28.6.56. 192 115 51
29.6.56. 154 93 26
29.6.56. 157 95 26
1.7.56. 176 105 36
3.7.56. 161 97 23
4.7.56. 136 82 13
4.7.56. 139 84 13
6.7.56. 158 85 0
Bata of the Regression. 
n = 12
r = 0.92, P <  0.001 
y = 0*94x + 71.8 
= 5.49 
= +12.24
- 1 0 6 -
P ig .  4»
Concentration-response curve : case 3
B. M.R. 
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(Table 6.
Basal metabolic rates and serum salicylate
concentrations; case 3 (Fig# 4).
02
B.M.E. Ser. Sal*
Date at K.T.P. fo Normal mg./lOO
14.1.56. 329 149 47
16.1.56. 315 142 49
17.1.56. 307 139 45
18.1.56. 327 148 44
21.1.56. 276 126 30
21.1.56. 264 120 29
22.1.56. 271 124 31
23.1.56. 278 126 35
24.1.56. 317 144 35
24.1.56. 322 146 31
25.1.56. 284 128 30
26.1.56. 288 132 29
28.1.56. 320 145 33
29.1.56. 324 147 46
30.1.56. 257 117 31
31.1.56. 257 117 28
31.1.56. 259 118 28
2.2,56. 250 114 16
9.2.56. 256 116 0
10.2.56. 258 118 0
10.2.56. 256 116 6
Data of the Regression. 
n = 18
r = 0.76, P<0.001 
y = l.llx + 93.7 
^  = 8.43 
^ +17.87.
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Pig» 5.
Concentration-response curve : case 4»
B. M.R.
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Table 7.
Basal metabolic rates and serum salicylate
concentrations; case 4 5)*
°2
ml./mln. B.M.E. Ser. Sal. 
Date at N.T.P. fo Normal mg./lOO ml.
1.7.55. 289 133 46
7.7.55. 267 122 47
8.7.55. 279 128 47
9.7.55. 281 129 52
11.7.55. 269 123 37
12.7.55. 255 117 40
14.7.55. 258 118 44
18.7.55. 221 102 19
19.7.55. 204 94 12
21.7.55. 246 113 24
22.7.55. 231 106 30
23.7.55. 246 113 37
25.7.55. 233 107 28
26.7.55. 223 102 14
27.7.55. 211 97 8
28.7.55. 223 102 0
1.8.55. 226 104 0
Data of the Regression. 
n = 15
r = 0.93, P<0.001 
y = 0.85x + 86.2 
= 4*66 
a <^=+10.07.
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Fig. 6.
Concentration-response curve : case 5.
B.MR.
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Table 8.
Basal metabolic rates and serum salicylate
concentrations; case 5 (Fig. 6).
°2
Date at N.T.P. io Normal mg./lOO
8.2.56. 264 165 45
10.2.56. 241 151 45
13.2.56. 265 166 49
14.2.56. 255 160 47
20.2.56. 251 157 40
21.2.56. 253 158 39
21.2.56. 248 155 37
23.2.56. 228 143 27
24.2.56. 222 139 24
27.2.56. 206 129 28
27.2.56. 196 123 28
28.2.56. 200 125 21
29.2.56. 197 123 10
29.2.56. 180 113 10
1.3.56. 218 137 19
5.3.56. 167 102 0
Data of the Regression. 
n = 15
r = 0.91, P<0.001 
y = 1.20X +105.25 
^  = 7 #38
t<^ r = +15.94.
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Pig. 7.
Concentration-response curve : case 6,
B.M.R.
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Table 9.
Basal metabolic rates and serum salicylate
conoentrations; case 6 (Big# 7)*
°2
Date
ml./mln. 
at N.T.P.
B.M.R.
io Normal
Ser.
mg./l
24.4.56. 210 118 0
25.4.56. 230 129 29
27.4.56. 184 103 34
28.4.56. 205 115 28
30.4.56. 280 158 55
1.5.56. 298 168 56
2.5.56. 249 140 52
3.5.56. 271 152 58
7.5.56. 300 168 74
8.5.56. 252 141 55
10.5.56. 183 102 38
11.5.56. 173 97 32
12.5.56. 167 94 17
14.5.56. 154 87 0
17.5.56. 173 97 0
25.5.56. 184 103 0
Data of the Regression, 
n = 12
r = 0.88, P <0.001 
y = 1.48x + 65.5 
= 15.83 
tSr- = +30.1
-114-
Fig. 8.
Concentration-response curve : case 7.
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Table 10.
Basal metabolic rates and serum salicylate 
concentrations; case 7 8).
°2
Date
ml ./min. 
at N.T.P.
B.M.E.
<fo Normal
Ser. Sal. 
mg./loo ml
20.6.55. 262 148 44
21.6.55. 217 123 40
22.6.55. 266 151 52
25.6.55. 253 143 50
24.6.55. 238 134 50
27.6.55. 243 138 51
28.6.55. 223 134 40
30.6.55. 208 118 39
1.7.55. 166 94 22
2.7.55. 198 112 28
4.7.55. 178 101 22
5.7.55. 159 90 10
5.7.55. 167 95 16
6.7.55. 174 99 15
16.7.55. 169 96 0
18.7.55. 168 95 0
Data of the Regression 
n = 14
r = 0.95, B <  0.001 
y = 1.37x + 73.1 
= 7.06 
t = +15.2.
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Table 12.
Serum salicylate concentrations and increments of
oxygen consumption; cases 1 to 7 (Pig. 10).
Patient (j.W* Case 1*
Ser. sal.
AOg cons.
2
mg./lOO ml. Cals./m /hr.
24 7.1
27 7.5
29 7.8
33 8.5
31 6.8
26 4.7
32 5.8
35 8.9
37 8.8
40 8.2
40 9.1
35 6.9
42 9.5
35 8.2
38 9.1
44 10.4
50 11.3
15 3.1
Table continued overleaf
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Table 12 (continued). 
Patient S.H# Case 2.
4 0o cons.
Ser. 8al. C. 2
mg./lOO ml. Cals./m /hr
43 13.2
44 11.0
47 10.3
46 9.6
33 7.1
51 11.0
26 3.2
26 3.8
36 7.7
23 4.6
13 —G • 4
13 0.1
Patient R.C. Case 3.
A Or) cons.
Ser. 8al. d. 2
mg./lOO ml. Cals./m /hr
47 12.2
49 9.5
45 8.7
44 12.0
30 3.2
29 1.1
31 2.4
35 3.5
35 10.1
31 11.2
30 4.5
29 5.1
33 10.8
46 11.2
31 0.0
28 0.0
28 0.2
16 —1.4
Table continued overleaf
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Table 12.(continued). 
Patient A.W. Case 4*
AOo cons.
Ser. sal. d O
mg./lOO ml. Cals./m /ir
46 11.6
47 7.6
47 9.8
52 9.9
37 7.9
40 5.6
44 5.9
19 -0.5
12 -3.7
24 3.8
30 1.2
37 3.9
28 1.4
14 —0.4
8 -2.4
Patient C.McC. Case 5.
AOo cons.
Ser. sal. d p
mg./lOO ml. Cals./m /hr
45 20.0
45 15.3
49 20.5
47 18.4
40 17.5
39 17.9
37 16.9
27 12.7
24 11.5
28 8.1
28 6.1
21 7.0
10 6.3
10 2.8
19 10.8
Table continued overleaf.
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Table 12. (continued). 
Patient J. McW. Case 6.
A Oo cons.
Ser. 8al. d p
mg./lOO ml. Cals./m /hr
29 12.6
34 3.3
28 7.7
55 22.5
56 26.3
52 16.3
58 20.9
74 26.6
55 17.1
38 3.1
32 1.1
17 —0.1
Patient M.Gr. Case 7.
AOo cons.
Ser. 8al. d p
mg./lOO ml. Cals./m /hr
44 19.8
40 10.2
52 20.7
50 17.7
50 14.5
51 15.8
40 11.4
39 8.3
22 —0.6
28 6.2
22 1.9
10 -2.1
16 —0.3
15 1.2
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Fig. 11»
Concentration-responae curve ; case 8.
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Table 13.
Basal metabolic rates and serum salicylate
concentrations : case 8 (Fig. 11).
°2
Date
ml./min. 
at N.T.P.
B.M.E.
^ normal
Ser. S 
mg./lOO
21.4.55. 165 78 0
22.4.55. 152 75 0
29.4.55. 170 81 24
2.5.55. 206 98 56
4.5.55. 195 95 50
6.5.55. 205 97 55
9.5.55. 219 104 45
10.5.55. 221 106 45
11.5.55. 227 108 46
12.5.55. 214 102 54
15.5.55. 159 76 16
Data of the Regression 
n = 9
r = 0.97, P<0.001 
y = l.OSx + 59.1 
<5i- = 2.87 
tSr = +6.8.
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Fig. 12.
Concentration-response curve : case 9.
B.M.R.
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Table 14#
Basal metabolic rates and serum salicylate
c one ent rat i ons1: case 9 (Pig. 12).
Date
°2
ml./min. 
at N.I.P.
B.M.R.
io Normal
Ser. Sal. 
mg./lOO ml.
7.7.55. 158 85 0
8.7.55. 160 86 0
9.7.55. 157 84 0
11.7.55. 155 83 18
12.7.55. 173 94 21
13.7.55. 176 95 31
14.7.55. 174 93 31
15.7.55. 190 102 36
16.7.55. 199 107 34
19.7.55. 207 112 37
20.7.55. 182 98 23
21.7.55. 188 102 30
22.7.55. 188 102 36
23.7.55. 218 117 44
25.7.55. 205 111 43
26.7.55. 210 114 49
28.7.55. 153 82 10
29.7.55. 151 81 9
Data of the Regression. 
n = 15
r = 0.95, P 40.001 
y = 0.99x + 69*2 
Sy = 4.78 
t <fr = +10.5 •
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13.
Concentration-response curve : case 10.
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Table 15.
Basal metabolic rates and serum salicylate
Date
°2
ml./min. 
at N.I.P.
B.M.E.
<fo Normal
Ser. Si 
mg./lOO
14.9.55. 122 63 0
15.9.55. 119 61 0
16.9.55. 116 60 0
16.9.55. 117 60 0
21.9.55. 160 82 32
22.9.55. 161 83 37
22.9.55. 160 82 36
24.9.55. 169 87 40
26.9.55. 159 82 34
27.9.55. 158 82 35
28.9.55. 165 85 36
29.9.55. 187 96 49
30.9.55. 187 96 56
2.10.55. 187 96 50
4.10.55. 189 97 53
5.10.55. 183 94 52
6.10.55. 164 84 37
6.10.55. 158 81 33
7.10.55. 128 66 24
7.10.55. 128 66 23
6.10.55. 139 71 20
Data of the Regression. 
n = 17
r = 0.96, PC 0.001 
y = 0.88x + 50.6 
= 2.85 
1 = +6.1
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Fig. 14.
Concentration-response curve : case 11.
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Table 16.
Basal metabolic rates and serum salicylate
Date
°2
ml./min. 
at N.T.P.
B.M.E.
io Normal
Ser. Sal. 
mg./lOO ml.
10.9.55. 141 81 0
12.9.55. 141 81 0
12.9.55. 130 79 0
13.9.55. 128 78 0
14.9.55. 131 80 0
21.9.55. 151 91 24
22.9.55. 159 96 30
23.9.55. 174 100 32
24.9.55. 160 93 32
27.9.55. 152 88 29
29.9.55. 173 100 40
30.9.55. 185 107 44
2.10.55. 176 102 46
3.10.55. 197 114 46
4.10.55. 198 114 52
5.10.55. 182 105 44
6.10.55. 156 90 28
6.10.55. 161 93 24
7.10.55. 143 83 16
8.10.55. 140 81 14
Data of the Regression. 
n = 15
r = 0.94, P <0.001 
y = 0.83X + 69.4 
= 5.58 
= +7.7.
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Fig, 15.
Concentration-response curve : case 12
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Table 17.
Basal metabolic rates and serum salicylate
concentrations; case 12 (Fig. 15)*
°2
Date
ml./min.
at N.T.P.
B.M.E. Ser. Sal. 
io Normal mg./lOO ml
15.9.55. 135 77 0
16.9.55. 137 78 0
21.9.55. 162 93 28
21.9.55. 157 90 29
22.9.55. 168 96 34
26.9.55. 188 108 38
28.9.55. 187 107 44
29.9.55. 196 112 52
30.9.55. 201 115 59
2.10.55. 186 107 52
4.10.55. " 166 95 44
5.10.55. 155 88 30
7.10.55. 137 78 20
7.10.55. 135 78 18
8.10.55. 130 74 16
12.10.55. 136 78 0
Data of the Regression. 
n = 13
r = 0.95) P^O.OOl 
y = 0.95% + 62.3 
^  = 4.43 
C = +9.8 •
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Pif:. 16.
Concentration-response curve : case 13
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Table 18.
Basal metabolic rates and serum salicylate
Date
ml./min. 
at H.T.P.
B.M.R.
io Normal
Ser. Sal. 
mg./lOO ml.
16.7.55. 156 83 0
18.7.55. 146 78 0
20.7.55. 136 72 15
21.7.55. 159 84 14
22.7.55. 158 84 23
23.7.55. 188 100 35
25.7.55. 185 98 40
26.7.55. 194 103 50
27.7.55. 174 93 44
28,7.55. 188 99 44
29.7.55. 200 106 46
30.7.55. 182 96 37
1.8.55. 175 93 24
3.8.55. 143 76 15
4.8.55. 139 74 9
Data of the Regression, 
n = 13
r = 0.92, P<0.001 
y = Q.73x + 68.3 
= 4*67
t6"r = +10.3.
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Table 19#
oxygen consumption; cases 8 to 1;
Patient M.McM. Case 8.
4 0o cons.
Ser. Sal. ^
mg./lOO ml. Cals./m /hr
24 2.1
36 7.8
30 6.2
35 7.5
43 10.0
45 10.3
46 11.2
34 9.2
16 0.3
Patient A.MoL. Case 9.
cons.
Ser. Sal. o
mg./lOO ml. Cals./m /hr
18 “0.6
21 2.5
31 3.0
31 2.6
36 5.3
34 6.8
37 8.1
23 4.0
30 4.9
36 4.9
44 10.1
43 7.7
49 8.6
10 —0.9
9 -1.3
Table continued overleaf
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Patient I. McGr. Case 10.
AOo cons.
Ser. Sal. o
mg./I00 ml. Cals./m /hr
32 6.5
37 6.7
36 6.5
40 7.9
34 6.3
35 6.1
36 7.3
49 10.8
56 10.8
50 10.8
53 11.0
52 10.1
37 7.1
33 6.2
24 1.5
23 1.5
20 3.2
Patient P.P. Case 11 #
40o cons.
Ser. Sal. o
mg./lOO ml. Cals./m /hr
24 3.0
30 4.4
32 7.0
32 4.6
29 3.2
40 6.9
44 9.0
46 7.5
46 11.1
52 11.3
44 8.5
28 3.9
24 4.8
16 1.6
14 1.1
Table continued overleaf
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Table 19•(continued). 
Patient M*B* Case 12.
40o cons.
Ser. 8al. & 2
mg./lOO ml. Cals./m /hr
28 4.8
29 3.7
34 5.9
38 9.4
44 9.3
52 11.0
59 12.0
52 9.1
44 5.4
30 3.3
20 —0.1
18 —0.4
16 -1.3
Patient P.A. Case 13.
Cûr, cons
Ser. Sal. 2
mg./lOO ml. Cals./m /hr
15 —2 # 6
14 1.3
23 1.2
35 6.2
40 5.7
50 7.2
44 3.9
44 6.2
46 8.2
37 5.1
24 4.0
15 —1 • 4
9 —2.1
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Pig. 19.
Concentration-response curve; case 14.
8. MR.
nor*n.(
14.0 -
130 -
120 -
lOO -
IO 2 0  3 0  4 0  S o  6 0
6ERUM  SALICYUATE m ,/lO O »^
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Table 20#
Basal metabolic rates and serum salicylate
concentrations : case 14 (Pig. 19).
Date
°2
ml./min. 
at N.T.P*
B.M.R.
io Normal
Ser. Sal. 
mg./lOO ml.
16.10.56. 238 129 49
19.10.56. 227 123 41
23.10.56. 216 117 28
26.10.56. 240 130 49
30.10.56. 228 124 40
2.11.56. 218 118 38
6.11.55. 229 124 64
7.11.56. 270 146 71
8.11.56. 242 131 51
9.11.56. 250 135 54
10.11.56. 233 126 55
11.11.56. 184 100 22
14.11.56. 189 102 0
11.12.56. 227 123 22
28.11.57. 223 120 16
29.3.57. 230 124 26
Bata of the Regression, 
n = 15
r = 0.67, 0.01
y = 0.38x + 108.9 
= 7*70 
=+16.6.
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Fig. 20.
Concentration-response curve; case 15.
B.M.R
norm»
170 -
160 -
l?0 -
130 -
120 -
lOO -
IO 2.0 30 4 0  S O
SERUM SALICYLATE mo/lOOm/'
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Table 21#
Basal metabolic rates and serum salicylate
concentrations ; case 15 (Fig. 20).
Sate
°2
ml./min. 
at H.T.P.
B.M.R.
% Normal
Ser. Sal. 
mg./lOO ml.
28.11.56. 242 112 0
30.11.56. 339 157 44
3.12.56. 400 179 59
5.12.56. 415 189 52
7.12.56. 347 161 54
10.12.56. 335 155 42
12.12.56. 321 149 43
14.12.56. 247 114 15
15.12.56. 235 108 0
17.12.56. 240 111 0
Data of the Regression# 
n = 7
r = 0.92, 0.001
j = 1.53x + 90.2 
=  10.56 
t<fv- = +25.88.
-1 4 0 -
Table 22.
Increase in pulmonary ventilation and oxygen consumption 
in convalescent patients. (Fig# 21).
Patient G.W. Case 1.
Date
UV2 L, #
2
Cals./m /hr.
A Pulm. Vent 
l./min.
1.12.55. 7.1 6.0
1.12.55. 7.5 3.4
2.12.55. 7.8 3.1
3.12.55. 8.5 1.6
5.12.55. 6.8 9.7
6.12.55. 4.7 3.0
6.12.55. 5.8 5.5
7.12.55. 8.9 7.8
7.12.55. 8.8 7.4
9.12.55. 8.2 11.1
9.12.55. 9.1 13.1
10.12.55. 6.9 8.2
11.12.55. 9.5 10.3
13.12.55. 8.2 8.6
14.12.55. 9.1 2.7
14.12.55. 10.4 5.0
15.12.55. 11.3 9.5
16.12.55. 3.1 6.2
Table continued overleaf
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Table 22♦ (continued).
Patient S.H. Case 2.
#
p A Pulm. Vent
Date Cals./m /hr. l./min.
20.6.56. 13.2 6.6
22.6.56. 11.0 6.5
22.6.56. 10.3 6.5
23.6.56. 9.6 5.1
25.6.56. 7.1 3.6
28.6.56. 11.0 5.1
29.6.56. 3.2 1.0
29.6.56. 3.8 1.0
1.7.56. 7.7 1.5
3.7.56. 4.6 0.9
4.7.56. —0.4 2.9
4.7.56. 0.1 2.9
Table continued overleaf
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Table 22. (continued). 
Patient E.G. Case 3,
Date
WiJLO #
2
Cals./m /hr.
A Pulm. Vent 
l./min.
14.1.56. 12.2 7.1
16.1.56. 9.5 3.8
17.1.56. 8.7 5.0
18.1.56. 12.0 4.3
21.1.56. 3.2 2.8
21.1.56. 1.1 3.1
22.1.56. 2.4 1.7
23.1.56. 3.5 2.5
24.1.56. 10.1 2.9
24.1.56. 11.2 4.4
25.1.56. 4.5 2.7
26.1.56. 5.1 1.3
28.1.56. 10.8 1.7
29.1.56. 11.2 1.5
30.1.56. 0 1.5
31.1.56. 0 0.9
31.1.56. 0.2 0.9
2.2.56. —1.4 1.1
Table continued overleaf
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Table 22. (continued). 
Patient A.W. Case 4.
AO^ cons.
Date Cals./m^/lir. l./m
1.7.55. 11.6 -9.1
7.7.55. 7.6 —4.1
8.7.55. 9.8 1.7
9.7.55. 9.9 5.2
11.7.55. 7.9 7.5
12.7.55. 5.6 —0.7
14.7.55. 5.9 -5.3
18.7.55. -0.5 -3.9
19.7.55. -3.7 —4.2
21.7.55. 3.8 -3.7
22.7.55. 1.2 0.4
23.7.55. 3.9 0.5
25.7.55. 1.4 —1.2
26.7.55. —0.4 -4.7
27.7.55. -2.4 —2.6
Table continued overleaf
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Table 22. (continued).
1 c .  McC. Case 5.
Date
AOp cons.
2
Cals./m /hr.
A Pulm. Vent 
l./min.
8.2.56. 20.0 4.1
10.2.56. 15.3 4.5
13.2.56. 20.5 3.8
14.2.56. 18.4 2.3
20.2.56. 17.5 2.3
21.2.56. 17.9 1.6
21.2.56. 16.9 0.8
23.2.56. 12.7 2.7
24.2.56. 11.5 0.4
27.2.56. 8.1 0.0
27.2.56. 6.1 -1.3
28.2.56. 7.0 -0.4
29.2.56. 6.3 0.2
29.2.56. 2.8 1.4
1.3.56. 10.8 —1 # 2
Table continued overleaf
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Table 22, (continued).
1 J.McW. Case 6.
Date
AOo cons.
2
Cals./m /hr.
A Pulm. Vent 
l./min.
25.4.56. 12.6 0.4
27.4.56. 3.3 2.8
28.4.56. 7.7 0.9
30.4.56. 22.5 3.9
1.5.56. 26.3 3.9
2.5.56. 16.3 2.6
3.5.56. 20.9 4.4
7.5.56. 26.6 4.4
8 .5.56. 17.1 7.4
10.5.56. 3.1 2.2
11.5.56. 1.1 3.2
12.5.56. —0 • 1 —0 • 4
Table continued overleaf
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Table 22> (continued).
Patient M.Gr. Case 7.
Date
"2
Cals./m /hr.
A Palm. Vent 
l./min.
20.6.55. 19.8 5.2
21.6.55. 10.2 5.7
22.6.55. 20.7 4.8
25.6.55. 17.7 5.9
24.6.55. 14.5 7.2
27.6.55. 15.8 8.7
28.6.55. 11.4 3.9
30.6.55. 8.3 2.8
1.7.55. “0.6 2.2
2.7.55. 6.2 1.4
4.7.55. 1.9 —0.6
5.7.55. -2.1 —1.0
5.7.55. -0.3 —0.9
6.7.55. 1.2 0.7
-147"
Table 23#
Increase in pulmonary ventilation and oxygen congumption 
in myxoedematous patients» (Fig# 22).
Patient M.M. Case 8.
Date
2
Cals./m /hr.
A Pulm. Vent 
l./min.
29.4.55. 2.1 -0.4
2.5.55. 7.8 1.8
4.5.55. 6.2 —0.1
6.5.55. 7.5 2.1
9.5.55. 10.0 1.8
10.5.55. 10.3 2.2
11.5.55. 11.2 1.2
12.5.55. 9.2 0.5
15.5.55. 0.3 -0.2
Table continued overleaf
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Table 23. (continued).
Patient A. McL. Case 9*
AO cons
2 2 
Date Cals./m /hr.
A Pulm. Vent 
l./min.
11.7.55. 0.6 2.9
12.7.55. 2.5 1.2
13.7.55. 5.0 1.8
14.7.55. 2.6 2.2
15.7.55. 5.5 2.2
16.7.55. 6.8 1.1
19.7.55. 8.1 2.5
20.7.55. 4.0 1.7
21.7.55. 4.9 3.2
22.7.55. 4.9 1.7
25.7.55. 10.1 3.0
25.7.55. 7.7 4.0
26.7.55. 8.6 3.4
28.7.55. -0.9 —0.2
29.7.55. -1.3 —1.0
Table continued overleaf
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Table 23, (continued)*
1 I.McG. Case 10.
Date
AO2 cons. 
Cals./m^/hr
A Pulm. Vent 
l./min.
21.9.55. 6.5 0.0
22.9.55. 6.7 0.8
22.9.55. 6.5 1.4
24.9.55. 7.9 -0.2
26.9.55. 6.3 0.4
27.9.55. 6.1 0.9
28.9.55. 7.3 0.0
29.9.55. 10.8 1.0
30.9.55. 10.8 1.0
2.10.55. 10.8 2.4
4.10.55. 11.0 1.1
5.10.55. 10.1 0.6
6.10.55. 7.1 —0.3
6.10.55. 6.2 0.8
7.10.55. 1.5 —0.1
7.10.55. 1.5 —0.5
8.10.55. 3.2 —0.2
Table continued overleaf
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Table 23. (continued).
; P.P. Case 11.
AOg cons.
2
Date Cals./m /hr.
A Pulm. Vent 
l./min.
21.9.55. 3.0 0.3
22.9.55. 4.4 0.2
23.9.55. 7.0 1.7
24.9.55. 4.6 0.6
27.9.55. 3.2 —0.6
29.9.55. 6.9 2.4
30.9.55. 9.0 1.1
2.10.55. 7.5 2.9
3.10.55. 11.1 4.0
4.10.55. 11.3 2.1
5.10.55. 8.5 5.2
6.10.55. 3.9 1.2
6.10.55. 4.8 1.2
7.10.55. 1.6 0.6
8.10.55. 1.1 -0.2
Table continued overleaf
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Table 23. (continued).
; M.B. Case 12.
Date
AOo cons.
2
Cals./m /hr.
A Pulm. Vent 
l./min.
21.9.55. 4.8 1.4
21.9.55. 3.7 1.3
22.9.55. 5.7 3.2
26.9.55. 9.4 1.9
28.9.55. 9.3 3.4
29.9.55. 11.0 6.7
30.9.55. 12.0 7.3
2.10.55. 9.1 6.4
4.10.55. 5.4 6.9
5.10.55. 3.3 1.4
7.10.55. —0.1 0.7
7.10.55. —0.4 —0.3
8.10.55. -1.3 1.6
Table continued overleaf
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Table 23» (continued).
: P.A. Case 13.
Date
AOg cons.
2
Cals#/m /hr.
A Pulm. Vent, 
l./min.
20.7.55. —2.6 0.2
21.7.55. 1.3 1.8
22.7.55. 1.2 1.4
23.7.55. 6.2 4.3
25.7.55. 5.7 —0.3
26.7.55. 7.2 2.4
27.7.55. 3.9 2.2
28.7.55. 6.2 1.4
29.7.55. 8.2 6.0
30.7.55. 5.1 5.5
1.8.55. 4.0 1.4
3.8.55. -1.4 2.8
4.8.55. -2.1 0.8
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Table 25*
Effect of salicylate on respiratory quotient and
nitrogen balance; Case 16 (Pig. 25).
Gaseous
ml./min.
Exchange 
at s. t. p. SerumSalicylate
Nitrogen
diff.
Date ^2 E.Q. mg./lOO ml. g*
24.4.56. 210 162 0.77 0 —2.68
25.4.56. 230 — — 29 +2.8
26.4.56. 248 179 0.72 — +0.71
27.4.56. 184 118 0.64 34 +2.22
28.4.56. 205 131 0.64 28 -5.4
29.4.56. -3.6
30.4.56. 280 129 0.46 55 -2.31
1.5.56. 298 179 0.60 56 —6.26
2.5.56. 249 207 0.83 52 —1.62
3.5.56. 271 200 0.74 58 -2.91*
4.5.56. -2.63*
5.5.56. —3.98
6.5.56. -1.37
7.5.56. 300 175 0.58 74 -3.6
8.5.56. 252 177 0.70 55 -2.62
9.5.56. -1.01
10.5.56. 183 157 0.86 38 -2.48
11.5.56. 173 167 0.97 32 -2.41
12.5.56. 167 172 1.03 17
13.5.56.
14.5.56. 154 167 1.09 0
15.5.56.
16.5.56.
17.5.56. 173 222 1.20 0
25.5.56. 184 176 0.96 0
* Patient vomited.
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Table 26.
Effect of salicylate on respiratory quotient and
nitrogen balance; Case 17 (Pig. 26).
Gaseous
ml./min.
A
Exchange gerum 
at s.t.p. Salicylate
Nitrogen
diff.
Date ^2 E.Q. mg./lOO ml. g.
7.3.56. 287 252 0.88 0 +3.54
8 .3.56. 345 276 0.80 26 +10.12
9.3.56. +2.97
10.3.56. 412 272 0.66 43 —6.64
11.3.56. +5.55
12.3.56. 448 264 0.59 47 -0.65
13.3.56. 457 279 0.61 52 +2.73
14.3.56. +7.43
15.3.56. 406 350 0.86 49 +6.65
16.3.56. —1.9
17.3.56. +4.3
18.3.56. +1.45
19.3.56. 416 308 0.74 47 +1.54
20.3.56. +3.72
21.3.56. +10.37
22.3.56. +5.15
23.3.56. +8.95
24.3.56. 294 211 0.72 37 —
25.3.56. —
26.3.56. 324 246 0.76 48 +3.64
27.3.56. +3.78
28.3.56. +8.23
29.3.56. +8.83
30.3.56. 394 295 0.75 57 +0.52
31.3.56. +5.36
1.4.56. +0.88
2.4.56. +7.04
3.4.56. 390 315 0.81 62 +3.28
4.4.56. 241 270 1.12 32 +2.19
5.4.56. 261 293 1.12 7 +6.42
6.4.56. 209 265 1.26 0 +4.57
7.4.56. +1.21
8.4.56. +6.03
9.4.56. +7.29
10.4.56.
11.4.56.
12.4.56. 224 184 0.825 0
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Table 27.
Effect of salicylate on respiratory quotient and
nitrogen balance; Case 18 (Fig. 27).
Gaseous
ml./min.
Exchange 
at s.t.p.
A A
Serum
Salicylate
Nitrogen
diff.
Date 2 E.Q. mg./lOO ml. g.
28.4.56 « 253 214 0.85 0
29.4.56. 0 -3.91 .
30.4.56. 0 -2.12
1.5.56. 332 253 0.76 43 -6.29
2.5.56. -4.99
3.5.56. 372 222 0.60 55 -5.07
4.5.56. 247 175 0.71 42 -1.85
5.5.56. -13.83
6.5.56. -9.29
7.5.56. 345 225 0.67 6 6 -9.3
8 .5.56. -5.23
9.5.56. 300 222 0.74 56 -7.33
10.5.56. ^ 5 .18
1 1 . 5 . 5 6 . 231 1 7 8 0.77 53 -2.05
12.5.56. 305 190 0.62 30
13.5.56.
14.5.56. 230 195 0.85 59
15.5.56.
16.5.56.
17.5.56. 257 188 0.73 41
18.5.56.
19.5.56.
20.5.56.
2 1 . 5 . 5 6 .
28.5.56. 215 214 1 . 0 29
4.6.56. 225 2 0 0 0.89 59
11.6.56. 230 181 0.79 50
18.6.56. 205 2 0 0 0.97 41
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Table 28.
Effect of salicylate on respiratory quotient and
nitrogen balance; Case 19 (Pig. 28).
Date O2 CO2 R.Q. mg./lOO ml.
U.JLJ. J. »
s-
15.5.56. 0 -0.79
16.5.56. 167 148 0.89 0 -0.70
17.5.56. 168 — — 0 +1.51
18.5.56. 0 +4.82
19.5.56. — +0.13
20.5.56. 323 200 0.62 52 —0.07
21.5.56. 292 205 0.70 50 +2 * 4
22.5.56. 234 165 0.705 46 -4.56
23.5.56. +1.37
24.5.56. 265 152 0.575 ■ 55 +4.23
25.5.56. 225 175 0.78 42 +2.08
26.5.56. +3.48
27.5.56. +0.52
28.5.56. 272 203 0.75 54 +1.42
29.5.56. +1.19
30.5.56.
31.5.56. 233 178 0.76 59
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Table 31 »
Plasma DNP concentrations and Increments of oxygen 
consumption; cases 20 to 24 (Pig. 31)»
Patient N.M. Case 20.
Plasma DNP 
mg./I.
40
36
33
48
43
23
15
AOg cons.
p
Cals./m /hr.
11.0
11.5
12.2
13.3 
9.9 :
13.7
11.3
Patient A.B. Case 21.
Plasma BNp 
mg./I.
47 
54 
38 
42 
52
48 
21 
12
AOp cons. 
Cals./m /hr.
13.1
18.7
10.8
15.1
17.1
11.2 
5.0
—0 • 8
Table continued overleaf
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Patient
Table 31. 
M.S. Case 22.
(continued)
Plasma DNP 
mg./I.
AOp cons.
2
Cals./m /hr
45 16.2
45 19.2
49 18.0
45 14.7
40 12.7
27 9.2
17 7.8
6 5.3
Patient M.B. Case 23.
Plasma DHP 
mg./l.
A0_ cons.
2
Cals./m /iir
30 11.6
44 19.3
15 15.6
48 20.1
46 18.0
39 14.9
44 15.8
20 6.4
14 6.4
9 4.4
Table continued overleaf
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Table 31. (continued).
Patient D.McP.
AOp cone. 
Plasma DNp p
mg./l. Cals./m /hr.
19 12.4
32 13.6
38 17.5
30 12.4
44 14.0
45 17.7
41 15.6
51 15.8
44 13.6
41 15.8
25 7.2
10 2.2
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Table 32.
Plasma DHP concentrations and increments of oxygen 
consumption; cases 25 to 27 (Pig. 33).
Patient M.A._ Case 25.
Plasma DHP 
mg./l.
32
32 
37 
35
33 
19 
11
9
AOp cons.
2
Cals./m /hr.
8.3
3.7
5.3 
7.1
8.3
2.8 
2.9 
0.2
Patient M.I. Case 26.
Plasma DHP 
mg./l.
40
62
55
50
54
55 
27 
20 
17
AOp cons.
2
Cals./m /hr.
14.9
19.8
15.2
11.7
16.7 
15.0
4.3
0.7
1.1
Table continued overleaf
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Table 32, (continued).
Patient W,M. Case 27.
Plasma DUP 
mg./l,
19
21
31 
26 
24
24
32
32
42 
30 
53
33 
46 
49 
49
43 
43
25 
17
6
AOp cons. 
Cals./m /hr.
3.6 
6.2
4.2
1.3
5.1
6.4
5.9
10.3
5.9
5.1 
11.1
5.7 
10.0
12.3 
14.8 
10.0 
10.9
8.4 
4.3
3.7
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Table 33*
consumption in diabetici patients.
(Pig. 34).
Patient H.M. Case 20e
AOo cons.éL
p A Pulm. Vent.
Date Cals./m /hr. l./min.
17.5.57. 11.0 0.0
22.5.57. 11.5 4.4
24.5.57. 12.2 0.7
25.5.57. 13.3 1.2
27.5.57. 9.9 3.6
30.5.57. 13.7 1.3
1.6.57. 11.3 0.0
Patient A.B. Case 21.
AO^ cons.2 p A Pulm. Vent.
Date Cals./m /hr. l./min.
3.7.57. 2.73 3.2
5.7.57. 3.89 4.2
8.7.57. 10.8 5.4
10.7.57. 15.1 2.4
12.7.57. 17.1 2.15
15.7.57. 11.2 1.6
17.7.57. 5.0 1.6
19.7.57. —0.8 1.4
Table continued overleaf
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Table 33. (continued).
Patient H.S. Case 22.
Date
AOp cons.
2
Cals./m /hr.
A Pulm. Vent, 
l./min.
13.5.57. 16.2 2.5
15.5.57. 19.2 3.0
16.5.57. 18.0 4.4
22.5.57. 14.7 6.0
24.5.57. 12,7 3.7
26.5.57. 9.2 3.4
28.5.57. 7.8 —0.4
30.5.57. 5.3 1.2
Patient M.D. Case 23.
Date
AOp cons.
2
Cals./m /hr.
A Pulm. Vent, 
l./min.
19.9.57. 11.6 2.2
20.9.57. 19.3 4.1
24.9.57. 15.6 1.8
25.9.57. 20.1 3.1
28.9.57. 18.0 3.1
30.9.57. 14.9 3.6
2.10.57. 15.8 2.7
3.10.57. 6.4 2.4
4.10.57. 6.4 2.3
6.10.57. 4.4 0.9
Table continued overleaf
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Table 33» (continued).
Patient M.McP. Case 24.
AOp cons.
A Pulm. Vent
Date
2
Cals,/m /hr. l./min.
24.10.56. 12.4 0.9
26.10.56. 13.6 1.4
27.10.56. 17.5 2.1
29.10.56. 12.4 1.5
31.10.56. 14.0 1.6
2.11.56. 17.7 1.5
3.11.56. 15.6 2.0
6.11.56. 15.8 1.7
8.11.56. 13.6 2.1
11.11.56. 15.8 2.1
12.11.56. 7.2 2.1
15.11.56. 2.2 1.0
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Table 34*
Increase in pulmonary ventilation and oxygen 
consumption in myxoedematous patients.
Patient M.A. Case 25.
Date
AOp cons. 
Cals./m /hr.
A Pulm. Vent 
l./min.
31.10.57. 8.3 1.5
2.11.57. 3.7 1.7
4.11.57. 5.3 2.4
6.11.57. 7.1 3.0
7.11.57. 8.3 4.3
8.11.57. 2.8 2.0
11.11.57. 2.9 0.9
13.11.57. 0.2 1.7
Patient M.I. Case 26.
Date
AOp cons.
2
Cals./m /hr.
A Pulm. Vent, 
l./min.
21.1.58. 14.9 1.0
23.1.58. 19.8 1.3
25.1.58. 15.2 3.1
28.1.58. 11.7 1.8
30.1.58. 16.7 2.8
1.2.58. 15.0 2.8
4.2.58. 4.3 —0.8
5.2.58. 0.7 0.3
6.2.58. 1.1 —0.3
Table continued overleaf
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Table 34. (continued)*
Patient W#M. Case 27.
Date
Lk\J^ *
2Cals./m /hr.
A Pulm. Vent 
l./min.
7.7.56. 3.6 2.2
8.7.56. 6.2 2.3
9.7.56. 4.2 0.8
10.7.56. 1.3 2.0
11.7.56. 5.1 2.8
12.7.56. 6.4 —0.9
14.7.56. 5.9 0.9
16.7.56. 10.3 3.2
17.7.56. 5.9 3.1
19.7.56. 5.1 2.9
21.7.56. 11.1 2.8
23.7.56. 5.7 1.0
26.7.56. 10.0 3.7
27.7.56. 12.3 3.2
28.7.56. 14.8 4.9
30.7.56. 10.0 8.0
31.7.56. 10.9 4.0
2.8.56. 8.4 3.0
4.8.56. 4.3 2.7
6.8.56. 5.7 -1.9
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